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 To estimate the delivered dose to the patient during intra-fraction or throughout 
the whole treatment, it is important to determine the contribution of dose accumulated at 
different patient geometries to the overall dose.  Dose mapping utilizes deformable 
image registration to map doses deposited on patient geometries at different times.  
Inputs to the dose mapping process are the irradiated and reference images, the 
displacement vector field, and a dose mapping algorithm.  Thus accuracy of the 
mapped dose depends on the DVF and dose mapping algorithm.  Dose mapping had 
been the subject of many research studies however, up to now there is no gold 
standard DIR or dose mapping algorithm.  This thesis compares current dose mapping 
algorithms under different conditions such as choosing the planning target and dose 
grid size, and introduces new tool to estimate the required spatial accuracy of a DVF.  
11 lung patients were used for this thesis work.  IMRT plans were generated on the end 
of inhale breathing phases with 66 Gy as the prescription dose.  Demons DVF’s were 
generated using the Pinnacle treatment planning system DIR interface.  Dtransform, Tri-
linear with sub-voxel division, and Pinnacle dose mapping algorithms were compared to 
energy transfer with mass sub-voxel mapping.  For breathing phase 50% on 11 patients, 
tissue density gradients were highest around the edge of the tumor compared to the 
CTV and the PTV edge voxels. Thus treatment plans generated with margin equal to 
zero on the tumor might yield the highest dose mapping error (DME).  For plans 
generated on the tumor, there was no clinical effect of DME on the MLD, lung V20, and 
Esophagus volume indices. Statistically, MLD and lung V20 DME were significant.  Two 
patients had D98 Pinnacle-DME of 4.4 and 1.2 Gy.  In high dose gradient regions DVF 
spatial accuracy of ~ 1 mm is needed while 8 to 10 mm DVF accuracy can be tolerated 
before introducing any considerable dose mapping errors inside the CTV.  By using 
ETM with mass sub-voxel mapping and adapting the reported DVF accuracy, the 
findings of this thesis have the potential to increase the accuracy of 4D lung planning.   
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1 Introduction 
Lung cancer is one of the most common cancers in the world; it is the leading cause of 
cancer death in men and women in the United States.  The American Cancer Society in the 
United States estimates that in 2015, 115,610 male and 105,590 female new cases of lung 
cancer will be diagnosed and 86,380 male and 71,660 female deaths will occur, accounting 
for 27% of all cancer deaths (The American Cancer Society in the United States, 2015). 
Radiation has been used for many years to treat cancer with many successes, [1] [2] 
yet designing a successful radiation treatment plan for lung cancer remains a challenge.  
This is primarily because the cancer resides directly within a critical structure to human life, 
the lung.  Tumor motion due to ventilation adds another challenge on the complexity of the 
treatment; motion can be up to 5 cm (Chen, et al. 2001).  This motion requires definition of 
a planning volume that encompasses the motion or requires complex methods such as 
tracking or gating the tumor position.  The  density of the lung (~0.3 g/cc) is different from 
most other normal tissue densities (~1 g/cc) which presents challenges for dose calculation 
algorithms due to the loss of radiation equilibrium; especially when small field sizes are 
used for treatment [3] [4].  The patient breathing cycle is patient specific but is 
approximately 5 seconds from inhale to next inhale.  During this time the lung volume is 
changing, the tumor moving, and the shape of lung and tumor are changing (or deforming) 
due to compression and relaxation of tissue.   
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While typical treatment plans are designed on one instance of patient geometry 
(planning geometry), the patient goes through multiple breathing cycles during radiation 
delivery which leads to differences in planned and delivered dose.  To estimate the total 
dose delivered, dose contribution from different geometries can be accounted for by 
mapping the dose from the source geometries to a planning (reference) geometry and 
adding them.  Estimating the delivered dose is limited by the accuracy of tissue voxel 
mapped from one breathing cycle to another, and by the accuracy of the dose mapping 
algorithm used to sum the doses. 
This thesis compares different dose mapping algorithms for 4D dose calculations as 
functions of the dose conformity level and dose voxel resolution variables, and introduces a 
novel method of dose evaluation called distance to dose difference (DTD) to estimate the 
required spatial accuracy of a displacement vector field.  In the context of lung cancer, this 
thesis reports required accuracy of a meaningful deformation vectors for patient cases. 
This chapter gives an introduction to the dissertation.  In chapter 2, dose mapping 
processes are introduced and dose mapping algorithms are described. In chapter 3 the 
thesis specific aims are described.  In chapter 4, patients’ data and treatment planning 
design are described.  Dose mapping methods are compared including consideration of 
dose conformity and dose grid resolution.  A distance to dose difference (DTD) tool is 
introduced in chapter 5 to estimate the required spatial accuracy of a displacement vector 
field used in dose mapping.  In chapter 6, a 3D-continuous distance to dose agreement 
(DTA) method is introduced and compared to a discrete DTA approach for DTD 
calculations. In chapter 7, DTD is implemented on patient cases and chapter 8 gives a 
summary of the thesis and a discussion of future directions. 
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2 Background 
In this chapter the dose mapping process is described, current dose mapping 
algorithms are introduced, and DVF spatial accuracy is discussed by introducing the 
distance-to-dose difference (DTD) principle. 
2.1 Dose mapping 
The dose mapping process combines dose computation, deformable image 
registration, and dose summation based on multiple anatomic positions. In this section, 
dose mapping algorithms are reviewed. 
2.1.1  Clinical need for dose mapping 
It is well established that tissue “damage” caused by radiation depends on the 
integral dose delivered to the tissue.  For tissues that change position as a function of time, 
knowledge of the integral dose requires tracking or mapping the dose between the various 
anatomic instances.  This mapping describes changes in delivered dose due to tumor and 
organ-at-risk deformations as they move with respect to the radiation beams.  Brock et al. 
[5], discussed the importance of including organ deformation in dose calculations.  They 
calculated dose to the liver by implementing a model that incorporates rigid body motion 
and deformation.  The author reported an average change in the prescribed dose to tumor 
of -0.4 Gy (range of -4.1 to 1.7 Gy).  In this case, the maximum change in the prescribed 
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dose (1.7 Gy) results in an overdose to a nearby OAR.  Similarly, if the minimum change in 
the prescribed dose occurs inside the tumor, this will result in under dosing the target. 
Schaly et al. [6], tracked the dose distribution delivered to tissue voxels in a prostate 
case.  They show that the largest dose differences in rectum, bladder, and seminal vesicles 
were 29%, 2%, and 24%, respectively, after the first fraction of radiation treatment 
compared to the planned dose. After 15 cumulative fractions, the largest dose differences 
in rectum, bladder and seminal vesicles were 23%, 32% and 18% respectively, compared 
to the planned dose.  The study showed that by performing dose mapping, the physicist or 
the MD can assess dose differences as compared to the planned dose.  Dose mapping will 
help in assuring the planned dose distribution was delivered in order to meet the desired 
treatment outcome. 
The need for dose mapping also depends on the type of the treatment.  For lung 
stereotactic body radiotherapy (SBRT) treatment, it is important to track the dose since 
SBRT is delivered in fewer fractions, treats smaller target volumes, delivers at higher dose 
rate, and extended fractional treatment time.  Zhao [7], investigated the dosimetric effect of 
intra-fraction tumor motion during gated lung SBRT delivery and found dose deviations to 
95% of the PTV (D95) up to 26% for fractional dose and up to 14% for total dose.   
2.1.2  Dose mapping process 
Inputs to a dose mapping process include images of the irradiated geometry (Source 
image), the reference geometry (Target image), a displacement vector field (DVF) which 
registers common positions in these geometries, and a dose evaluation or mapping method 
[Figure 1].   
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Deformable image registration aligns images contents taken at different times by 
providing a DVF that maps voxels in the target anatomy (fixed reference image) to the 
corresponding voxels in the source image (moving image).  Once a DVF is generated it can 
be used to map intensity, contours, density, energy or dose.   
Dose mapping uses the DVF to pull or push dose or dose related information from 
the irradiated source image and scores it to the target image.  Figure 1 shows a simple 
graph of dose mapping; dose computed on an irradiated image (left) is mapped to voxels in 
a target image (right).  The accuracy of the dose value scored back at the target depends 
on the accuracy of the DVF used and on the dose mapping method to estimate the dose in 
the irradiated geometry.   
 
 
Figure 1: On the left is the irradiated image (source); target image is on the right.  Blue vectors represent DVFs 
that pull information from the source image to target image. 
 
 
2.1.3 Eulerian or Pull mapping method 
The pull mapping method (Eulerian transformation) is one method to map the source 
image dose to the target image.  Conceptually, the Eulerian transform pulls information 
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from a fixed position ܚ௦ in the source image to its corresponding originating position in the 
target image (ܚ௧), e.g. ܚ௧ ൅ ߮ሺܚ௧ሻ ൌ ܚ௦, where ߮ሺܚ௧ሻ is the displacement vector field at 
position ܚ௧.  Interpolation of the dose value at the position in the source image coordinate 
space is used to estimate the corresponding value as defined in the domain of the target 
image.  That is, by mapping information from ܚ௧ → ܚ௦, ߮ሺܚ௧ሻ enables pulling information 
(intensity, dose, energy and mass) from the source image ሺܵሻ back to the target image ሺܶሻ.  
2.1.4  Lagrangian or Push mapping method 
The push mapping method utilizes a Lagrangian transformation to map source 
image dose points to the target.  In this case, the DVF ߮ିଵሺܚ௦ሻ is defined in the coordinate 
space of the source image ሺܵሻ, and information (intensity, dose, energy and mass) is 
pushed from the source image to the target image; e.g. ܚ௦ ൅ ߮ିଵሺܚ௦ሻ ൌ ܚ௧.  In the push 
method, coordinates ܚ௧ are unlikely to land on the rectilinear coordinate space of image ܶ, 
therefore, for point-based quantities, values on the rectilinear coordinates of image space ܶ 
need to be determined by interpolation or averaging of adjacent points.  In this dissertation, 
however, the push mapping method is only used  in the context of the ETM algorithm 
(Section 2.2.4), where energy deposition points in ܵ are mapped to voxel volumes in ܶ and 
masses in sub-voxels of ܵ are mapped to voxel volumes in ܶ, circumventing the need for 
interpolation  
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2.2 Introduction to dose mapping methods 
2.2.1 Center of voxel approach 
In the center of voxel (COV) approach, graphically shown in Figure 2, the dose value 
pulled by the DVF and stored at a corresponding target voxel is the dose value from the 
center of the source voxel, even though the point transformed by the DVF may not lie at the 
center of the source voxel.  The COV approach uses the nearest neighbor interpolation. 
Flampouri [8] used the COV method to estimate the difference between planned and 
delivered dose due to respiratory motion for lung treatments.  The author generated 4 IMRT 
plans with different margins around the CTV.  The authors found that the difference in CTV 
equivalent uniform dose (EUD) between the planed and the delivered doses was 33, 11, 1 
and 0 Gy for the 4 IMRT plans used in the study. 
While the COV approach might improve dose estimates compared with neglecting 
deformable voxel motion, it is an approximation which is sensitive to absolute voxel 
 
 
 
 
 
 
Figure 2: Center of voxel approach adapted from (Flampouri, Jiang et al. 2006), Reference dose 
grid image on the left and source image on the right.  The thick black lines represent the voxel 
boundaries.  The center of the voxel in the reference image (end of exhale in this study) is mapped 
onto the source image, and the dose received by that voxel is directly approximated by the dose 
delivered to the overlaying voxel in the source image. 
Irradiated (source) Reference (target) 
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positions with respect to dose gradients; e.g. dose gradients over the voxel volume are 
ignored [9]. 
2.2.2 Tri-linear interpolation method    
To correct for some of the inherent limitations of the COV method, in the Tri-linear 
interpolation method (Figure 3), voxel centers (ܚ௧ሻ	from the reference target image are 
mapped to the source image (ܚ௧ ൅ ߮ሺܚ௧ሻ ൌ ܚ௦).  The dose value at ܚ௦ is interpolated via tri-
linear interpolation from the 8 surrounding dose points on the rectilinear source dose 
matrix.  The interpolated dose value is assigned to be the dose at ܚ௧.	 
Schally [6], implemented the Tri-linear method to estimate the difference between 
the planned and delivered dose for a prostate treatment site due to inter-fraction motion.  
The author reported differences in the bladder, rectum and seminal vesicles between the 
planned and the delivered dose.  By using 8 surrounding dose points on the rectilinear 
source dose grid, the tri-linear method estimates the mapped dose better than the COV 
method ; however, it is limited by its accuracy to interpolate dose in regions where dose 
point values change dramatically. 
                               
 
Figure 3  Tri-linear dose interpolation method (adapted from Rosu (Rosu, Chetty et al. 2005)).  On the left is the 
reference dose grid; on the right is the source dose grid.  A point C in the reference dose grid moves to a new location  in 
the source dose grid, then the dose to  is estimated by the Tri-linear interpolation of the doses at the closest neighboring 
dose grid points a, b, c and d.      
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2.2.3 Octant subdivision method 
To further improve dose mapping accuracy, Rosu [9], developed and implemented 
octant subdivision mapping method [Figure 4].  In this method, each target dose voxel is 
subdivided into octants sub-voxels.  The dose at each sub-voxel center is computed via tri-
linear interpolation method, and the dose at the target voxel center is assigned to be the 
average of the octant dose values.   
 
Figure 4: adapted from [9], tri-linear dose mapping method with octant subdivision.  Reference image is on the 
left and source image on the right.  The voxel in the reference image is divided into 4 octants, the center of each octant (1, 
2, 3, 4) is mapped to the source image and the dose for each point (૚̍, ૛̍, ૜̍, ૝̍) is interpolated from the known dose point 
around each point.  The final dose is mapped back to the reference image.   
 Rosu et al. compared octant subdivision with Tri-linear mapping method under 
variable conditions including dose grid resolution (3.5, 5 and 10 mm) for 6 patients using 
PTV-based plans with GTV-PTV margin of 1 cm.  She concluded that the dose grid 
resolution has no effect on mean lung dose (MLD) and EUD but does affect the NTCPs for 
serial organs such as the esophagus.  Other organs at risk were not included in their study.  
Rosu et al. also reported that increased dose differences can occur in regions of high dose 
gradients for different mapping methods.  Dose interpolation methods (DIM) do not give a 
reliable estimate of mapped dose in steep dose gradient regions because of voxel density 
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averaging, and due to the non-uniform melding of energy and mass which leads to a dose 
calculation error[10]. 
 
 
2.2.4   Energy transfer method   
The inherent limitation of dose interpolation methods in dose gradient regions is due 
to the fact that it intrinsically violates the definition of dose.  
 ܦ݋ݏ݁ ൌ 	ܦ ൌ ఌ௠	( ICRU.  Radiation quantities and units.  Report No.33) where ߝ is the 
energy deposited in the voxel and ݉ is the voxel mass.  When a deformation occurs 
between ܵ and ܶ, there is a re-arrangement of voxel contents, with voxels splitting, 
merging, and otherwise deviating from their original contents.   
Consider two voxels in S, ܦௌଵ ൌ ଵଵ ൌ 1 and ܦௌଶ ൌ
ସ
ଶ ൌ 2 which merge into a single 
voxel in ܶ.  A dose interpolation method will evaluate the dose as ܦ் ൌ ሺ஽ೄభା஽ೄమሻଶ ൌ
ଷ
ଶ, while, 
by definition ܦ் ൌ ሺଵାସሻሺଵାଶሻ ൌ
ହ
ଷ, which introduces a dose error of 16.67% [10]. 
To overcome this limitation, Siebers and Zhong [10] implemented a Monte Carlo-
based energy transfer method (ETM) for dose mapping.  Standard Monte Carlo dose 
computations inherently compute dose via its definition; ܦ ൌ ఌ௠, where ߝ is the sum of the 
energies deposited in the voxel and ݉ is the voxel mass.  In ETM, particle transport takes 
place in the source ܵ image space as usual, however, in addition to scoring energy 
deposition events in the source image space, they are also scored in the target image 
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space at the coordinates ܚ௧ ൌ ܚ௦ ൅ ߮ିଵሺܚ௦ሻ.  At the end of the simulation, for each target 
voxel, the integral energy deposited is divided by the mass to get the dose.  
													 											 
									ܦܚ் ൌ 	 ߝܚ்݉ܚ் 
 
(1) 
 
 Siebers and Zhong [10], developed and implemented ETM on a phantom case. In 
this thesis, specific aim one, ETM will be utilized for lung patient cases and compared with 
DVM and DIM methods.   
2.2.5   Energy and mass congruent method (EMCM) 
Conceptually, ETM will provide the proper mapped dose, however, as is evident in 
Equation 1, errors in the assessment of ݉ܚ் will directly translate into errors in dose.  
Zhong [11] developed EMCM to ensure consistency in energy deposited and mass in ETM.  
In EMCM, the mapped energy deposited is accumulated during particle transport simulation 
and the mapped mass is determined by using a Lagrangian mapping method to map n sub-
voxels from the irradiated source geometry to the target geometry to determine the 
phantom mass.  In order for the energy deposition to be congruent to mass mapping, the 
Zhong et al. point out that there should be a sufficient number of mass sampling points, and 
found that 64,000 sampling point is enough to ensure the energy and mass congruent.  
EMCM was applied on one patient case and mass sampling for 106x86x35 dose grid with 
each voxel partitioned into 125,000 sub-voxels took 45 min. 
2.2.6   Direct voxel tracking method 
Monte Carlo dose calculations have no requirement that the patient transport 
geometry be on a rectilinear grid.  Realizing this, Heath et al. developed a voxel warping 
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method (VWM) in which each voxel in the reference target anatomy is mapped to two 
tetrahedral volumes in the source reference space.  The tetrahedral corners were mapped 
via Lagrangian coordinate transform, and the voxel mass was directly translated from the 
target to the source geometries.  Using this method, the dose in the reference geometry 
was set as the average of the doses of the composite tetrahedral elements.  
Heath et al. [12], developed, implemented and compared VWM with DIM for lung 
cancer treatments and found that, for realistic treatment planning scenarios no clinically 
significant differences were noted between DIM and VWM calculations.  However, for an 
extreme case where (1.2 cm) target motion was not included in the plan, the target volume 
coverage was underestimated by up to 16% by DIM methods.  The authors reported that 
care must be taken in choosing the dose mapping method when the organ at risk or the 
tumor moves into a region of high or low dose gradients; however, they did not study the 
effect of such error directly on organs at risk. 
2.2.7   Dtransform 
Heath [13] (Figure 5) also developed a volume based mapping method for mapping 
the energy deposited in a deformed geometry to reference geometry, which is conceptually 
similar to the ETM described by Siebers and Zhong [10].  While ETM requires a Monte 
Carlo dose calculation, Dtransform can be applied to an arbitrary dose calculation.  Instead 
of mapping the energy depositions point by point, the fraction of the energy deposited in 
each deformed voxel (in the irradiated image) is mapped to each reference voxel as 
determined by the intersection of the warped reference voxels and the voxels of the 
deformed geometry. 
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Heath compared dtransform to VWM on a phantom case and on a patient case.  
She found that, when an exact transformation between the reference and target geometries 
was provided, the voxel and Dtransform methods produced identical results. However, 
when the transformation is not exact, there were discrepancies in the energy deposited on 
the target geometry which lead to significant differences in the dose calculated by the two 
methods due to registration errors.  
 
Figure 5: Illustration of energy mapping in two dimensions adapted from [13]. Each tetrahedron n of the 
reference grid is mapped to the target grid, and the fractional volume V (j) ∩ T {Vn(i)} of each target voxel overlapped by 
the deformed tetrahedron is calculated. 
2.3 Analysis of dose mapping error 
Dose mapping error (DME) is defined as the difference in dose between two dose 
mapping methods, assuming one of them is the gold standard.  Most of the dose mapping 
studies report that dose mapping errors occur in steep dose gradient regions; however, the 
presence of high dose gradients is a sufficient but not necessary condition for DME to 
occur.  According to the work done by Siebers et al. [10], several variables effects DME, 
the accuracy of the DVF, high dose and density gradient regions in the irradiated geometry. 
For an artificial DVF with value of zero for all voxels, DME is zero even in the 
presence of high dose and tissue density gradients since no interpolation is done.  Similarly, 
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for a DVF with a rigid shift for all voxels equal to the voxel size, DME is also zero since 
mapped dose is identical to the pre-mapped dose. 
It is when the DVF is not accurate or has non rigid shifts DME might not be zero, 
depending on tissue density gradients in the irradiated geometry.  This is explained with an 
intuitive example from Siebers et al, [10].  The example demonstrates a case where two 
tissue voxels in exhale geometry (ݒ1	and 	ݒ2) merge into one voxel in the inhale geometry 
(ݓ1), as shown in Figure 6.   
 
 
Figure 6: adapted from [10], voxel ࢜૙ is directly mapped to voxel	࢝૙, voxels ࢜૚ and ࢜૛ are merged into 
voxel	࢝૚, and voxel ࢜૜ is directly mapped to voxel	࢝૛. 
In this case, a DIM method estimates the mapped dose to	ݓଵ by the following 
equation: 
݀஽ூெሺݓଵሻ ൌ 	݀ௌ→ோ஽ூெሺݓଵሻ ൌ ௗሺ௩ଵሻାௗሺ௩ଶሻଶ ൌ
ಶሺೡభሻ
ಾሺೡభሻା
ಶሺೡమሻ
ಾሺೡమሻ
ଶ                                        (2) 
where 	ܧሺݒ௫ሻ and 	ܯሺݒ௫ሻ are the energy deposited and the mass in voxel	ݒ௫.  However, the 
ETM computes the dose mapped to voxel ݓଵ as 
்݀ሺݓଵሻ ൌ 	 ாሺ௩ଵሻାாሺ௩ଶሻ	ெሺ௩ଵሻାெሺ௩ଶሻ= 
ௗሺ௩ଵሻାௗሺ௩ଶሻఊ
ଵାఊ , ߛ ൌ
ெሺ௩ଶሻ
ெሺ௩ଵሻ                                           (3) 
DME can be written as the dose difference between ݀஽ூெሺݓଵሻ and ்݀ሺݓଵሻ 
ܦܯܧ ൌ |ሺௗሺ௩ଶሻିௗሺ௩ଵሻሻ∗ሺଵିఊሻ|ଶ∗ሺଵାఊሻ                                                                          (4) 
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From equation (4), we can conclude that no matter how big the dose gradients in the 
irradiated geometry, if the geometry is homogenous (ߛ ൌ 1ሻ, then DME = 0.  Cases where ߛ 
≠ 1 (heterogeneous irradiated medium) and steep gradient regions lead to non-zero DME. 
2.4 DVF accuracy requirements 
No matter which dose mapping method is used, if the DVF is not perfect and the 
irradiated dose distribution is heterogeneous, dose mapping errors will occur.  The key to 
reducing dose mapping uncertainty is not only dependent on the mapping method itself but 
to a high extent on the uncertainty in the displacement vector field used to perform dose 
mapping.   
There are numerous DIR algorithms to calculate the DVF, however no known 
algorithm provides a DVF that maps tissue elements between anatomic instances without 
error [14-21].  In addition to developing ways to reduce DVF uncertainty, we need to ask 
the question: what is the required accuracy in the DVF?  In other words, we might not have 
a perfect DVF; however we can accept a DVF with uncertainty if that uncertainty does not 
affect the dose.   
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3 Specific Aims 
As described in Chapter 2, two sources of error affect dose mapping accuracy: 
(1) commonly used interpolation-based dose mapping method have inherent limitations 
when dose gradients overlap tissue density gradients and (2) erroneous displacement 
vector fields can map incorrect dose to the reference target image.  Prior works with 
respect to (1) have been limited to few (<6) patient studies and with respect to (2), prior 
works have expended substantial efforts to reduce DVF and quantify DVF uncertainty 
without consideration of the DVF accuracy requirements.  This dissertation addresses the 
clinical implications of dose mapping and its associated inaccuracies by pursuit of the 
following specific aims:  
3.1 Specific Aim I:  Dose mapping error quantification 
To determine the potential clinical significance of dose-mapping error inherent in dose 
mapping methods for intra-fraction dose mapping for clinical lung radiation therapy patients 
as functions of dose matrix resolution and planning target definition.   
Using ETM-EMCM as a standard, dose mapped via ETM-EMCM, dtransform, and 
DIM using 2-different voxel resolutions are compared for a series of 11 lung patients with 
10-phase 4D CT data.  In particular, two dose mapping variables are investigated, (1) the 
dose matrix resolution used for the primary dose calculation, testing the hypothesis that as 
the voxel size decreases, the DME will decrease and (2) the conformity of the dose with 
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respect to tissue density gradient regions, testing the hypothesis that DME will be greatest 
where tissue gradients and dose gradients overlap.   
3.2 Specific Aim II: Distance-to-dose difference (DTD) tool 
To develop and describe a distance-to-dose difference tool which quantifies the 
maximum permitted DVF error at each voxel location that will ensure that the dose mapping 
error introduced is less than a pre-specified clinically relevant tolerance. 
The DTD tool is initially developed based using a standard discrete distance-to-
agreement algorithm.  Due to the interpolation error inherent in the discrete algorithm, a 
continuous distance-to-agreement algorithm is implemented for the DTD calculation 
(Chapter 6).  Continuous and discrete DTD are compared on a phantom and patient case.  
The continuous DTD algorithm is applied to the lung patient cases to quantify DVF 
accuracy requirements for those patients (Chapter 7). 
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4 Dose mapping algorithms comparison 
As discussed in Chapter 2, dose mapping accuracy depends on the DVF used to map the 
dose and on the dose mapping algorithm used to transfer the dose.  This chapter 
addresses the later.  The various dose mapping algorithms described in Section 2.2 can be 
classified as being point based (COV and DIM methods) or volume based (ETM, VWM, 
dtransform) algorithms.  One goal of this dissertation is to study the potential clinical effect 
of using point based versus volume based dose mapping algorithms on the accumulated 
4D dose for lung treatment site.  This chapter tackles this thesis aim by implementing ETM 
with congruent mass mapping and comparing these results with the interpolation-based 
mapping algorithm included in the Pinnacle3 treatment planning system, tri-linear 
interpolation with sub-voxel division and dtransform (volume based) on 11 lung cancer 
patients, each with a 10 phase CT. 
The first part of the chapter discusses patient data, tumor motion extent, and 
treatment planning design.  The implementation of tri-linear interpolation with subvoxel 
implementation is described in the second part.  The third part investigates target volume 
characteristics which should highlight differences between the point-based and volume-
based dose calculation algorithms.  The fourth part tests the hypothesis that DIM and 
EMCM algorithms converge to similar results when a dose grid size of 2×2×2 ݉݉ଷ		is used 
for dose calculation on the planning phase.  
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4.1 Patients and plans 
4.1.1  Patient data 
The patient data for this thesis has been collected from Project 4 of the VCU Program 
Project Grant (PPG) [NIH-P01-CA116602] and one patient data was obtained from the MD 
Anderson Cancer Center in Houston, Texas.  The imaging data was obtained in 
accordance with approval of Institutional Review Board (IRB) protocol.  The study 
examines 11 lung cancer patients.  Although each patient has several 4DCT data sets, only 
one 4DCT image comprising 10 images each acquired to capture the full breathing cycle in 
10 phases (phase 0% to 90%) was necessary for this thesis.  For each patient, tumor 
motion was characterized by the motion of the tumor center-of-mass between breathing 
phases.  The extent of tumor motion in each of the superior-inferior (S.I), anterior-posterior 
(AP) and lateral directions is shown in Table 1.  
Table 1: The extent of patient tumor motion in left anterior (LAT), anterior posterior (AP), and superior inferior (SI) 
directions in cm for the 11 patients used in this study. 
Patient number        LAT        AP         SI 
3D motion    
vector 
100  0.05  0.15  0.23  0.28 
101  0.25  0.32  0.56  0.69 
102  0.28  0.21  0.17  0.39 
103  0.07  0.08  0.57  0.58 
104  0.41  0.3  0.41  0.65 
105  0.19  0.16  0.43  0.49 
106  0.13  0.21  0.22  0.33 
107  0.08  0.24  0.31  0.40 
110  0.15  0.44  0.61  0.77 
114  0.16  0.36  0.86  0.95 
MD Anderson 38  0.06  0.26  2.4  2.41 
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4.1.2 Planning 
Treatment planning requires a set of contours for specification of target tissues to be 
treated and normal tissues to be avoided by the radiation.  For each patient, gross tumor 
volumes (GTVs) were contoured on each phase of a 10 phase image set by a single 
physician.  A clinical target volume (CTV) on each breathing phase was created by adding 
an isotropic-8 mm margin to each GTV.  The internal target volume (ITV) was produced by 
the union of per-phase CTVs.  The PTV was created on breathing phase 0% (the planning 
phase) by adding an isotropic 5 mm margin to the ITV, unless otherwise specified.  Spinal 
cord and esophagus contours on breathing phase 0% were expanded by 5 mm each to 
obtain organ at risk volumes (PRVs).  The phase 0% total lung volume was defined as the 
sum of the right and left lung minus the CTV volume.  A normal tissue structure was 
created on the planning phase by expanding the CTV by 4 cm and avoiding the interior of 
CTV expanded by 1 cm.  These margins constitute the default margin setting for this study 
and conform to standard clinical practice.  Zero margin plans (directly on the tumor) were 
also generated to permit determination of dependencies on dose conformity.   
 IMRT planning on phase 0% was performed with the Pinnacle Treatment Planning 
System (Philips Medical Systems research version 9.100) using direct machine parameter 
optimization (DMPO).  In general, six to nine 6-MV coplanar non-opposed photon beams 
were chosen with angles depending on the tumor location.  The prescribed dose was 66 Gy 
to 98% of the PTV volume [RTOG protocol 98-03].  The following constraints were applied 
on all the patient plans for this thesis.  The lung volume receiving 20 Gy or more (V20) was 
not to exceed 30%.  The heart volume receiving 40 Gy or more (V40) should not exceed 
50%.  No more than 55 Gy (V55) to 30% of the esophagus PRV.  The maximal dose (D1) 
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to the spinal cord PRV should not exceed 45 Gy.  The maximum dose to the normal tissue 
structure should not reach the prescribed dose 66 Gy.  The maximum dose received by the 
PTV should be limited to 74 Gy. Table 2 lists the planning objectives for the PTV, spinal 
cord PRV, normal lung, esophagus PRV, heart and normal tissue ring used to generate the 
plans.    
 
Table 2: Planning objectives for the 11 non SBRT lung patients for the PTV and each OAR or PRV. 
Regions of interest Type Dose (Gy) Volume (%) 
PTV Minimum DVH 
Maximum dose
66 
74 
98 
- 
Spinal cord PRV Maximum dose 42 - 
Normal lung Maximum DVH
Maximum dose
18 
74 
30 
- 
Esophagus PRV Maximum DVH
Maximum dose
53 
74 
30 
- 
Heart Maximum DVH
Maximum dose
40 
74 
50 
- 
Normal tissue Maximum dose 66 - 
 
The displacement vector fields used to deform the dose (using DIM and Dtransform) from 
all the breathing phases to the planning treatment plan were generated in Pinnacle using 
the Demons algorithm with the end of inhale phase as the fixed image and phase 10-90% 
as the moving images. 
4.2 Dose mapping implementation 
In this section, I discuss the inputs to each dose mapping algorithm such as the source 
dose computation algorithm and the DVF’s used.  A description of the implementation of 
each dose mapping algorithm will also be given. 
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4.2.1 Inputs 
 
Table 3 lists the inputs used for ETM, Dtransform, Tri-linear sub-voxeling, and 
Pinnacle dose mapping algorithms.  Figure 7 shows the flow diagram of the dose mapping 
algorithms comparison. 
Table 3: Inputs used to each dose mapping algorithm. N is the number of irradiated (source) breathing phases 
from 10% to 90%. No mapping occurs from target breathing phase 0% to 0%. 
Dose mapping 
algorithm 
Source 
dosephase N% 
Energyphase N% Mass 
 
DVF 
 
EMCM  Transported on source by MC 
Deformed source 
mass 
Pseudo-inverse 
phaseN%to0% 
Dtransform MC  Source and target  phase0%toN% 
Tri-linear n=1 MC   phase0%toN% 
Tri-linear n=2 MC   phase0%toN% 
Tri-linear n=3 MC   phase0%toN% 
Pinnacle MC   Phase0%toN% 
         
 23 
 
 
Figure 7: Flow diagram that shows the dose mapping algorithms comparison process. The two-sided arrow 
between the various dose mappings to phase 0 indicate the comparison between these methods. 
4.2.1.1 MC dose algorithm 
MC has been used in Medical Physics for decades [22], [23], [24], [25], [26], [27].  
MC dose computations are based on simulation of the paths and physics probability 
interactions of photon/electron particles through the accelerator head, beam modifiers, and 
patient geometry [28], [29], [30].  The MC method for dose computation has been shown 
through many research studies to calculate accurate dose distributions for clinical 
radiotherapy, particularly in heterogeneous patient tissues where the effects of electron 
transport can’t be accurately handled with conventional, deterministic dose algorithms [31], 
[32] [33], [30], [34], [35], [36], [37], [38], [39], [40], [41] , [42] , [43].  
MC calc on  
iphase ܦெ஼௜ 
 
ܦ஽ூெ଴ 
DIM 
mapped dose 
(0→i) 
ܦா்ெ଴ 
EMCM 
mapped dose 
(i→0) 
ܦ஽௧௥௔௡௦଴ 
Dtransform 
mapped dose 
(0→i) 
ܦ௉௜௡଴ 
Pinnacle 
Mapped dose 
(0→i) 
0→i(pull method) 
i→0(push method) 
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Since the ETM mapping algorithm is based on transporting the energy on the source 
geometry, MC dose on each breathing phase was computed by running the ETM mapping 
method first.  An in-house MC dose calculation system [31] which utilizes several 
components of the BEAMnrc/EGSnrc [26] system was used for dose calculations.  Source 
particles for the simulation were sampled from a previously commissioned rotationally 
symmetric phase space generated from a BEAM simulation for the 6 MV mode of a Varian 
Cl21EX treatment machine [38].  Particle transport in patients was simulated with a 
modified version of DOSXYZnrc MC code [44].   
The computed per phase MC dose was used as a source dose input to the rest of 
the DIM and Dtransform methods to be consistent and to avoid dose-calculation algorithm 
dose differences.   
4.2.1.2 DVF’s 
The DVF’s used for this thesis work were generated by the Pinnacle TPS which 
uses the Demons DIR algorithm to compute the DVF’s [45], [46], [45].  Demons DIR 
algorithm is a mono-modality algorithm that implicitly assumes a structure is represented by 
voxels of the same intensity in both source and target images.  This makes the DVFs 
generated sensitive to image artifacts; this issue, however, is outside the scope of this 
thesis and should not affect the dose mapping algorithm comparison since the 
implemented dose mapping algorithms use the same DVFs. 
Since the dose is mapped from breathing phases N% (N= 10, 20, 30 , 40, … 90) to 
0%end of inhale breathing phase, the input DVFs were the DVFs that point from breathing 
phase 0% to N% and were generated using the TPS Syntgra graphic user interface.  The 
(0% to N%) DVFs were used for each of the DIM and Dtransform dose mapping algorithms.  
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The EMCM mapping algorithm utilizes the forward DVFs (source to target) to push the 
energy from the source to target image.  To minimize dose mapping error due to input 
DVFs directions, a pseudo inverse DVF was generated using in-house algorithm [17] and 
used as an input for the EMCM method.  The advantage of using the PIDVF is that it 
preserves the location of information mapped back-and-forth between image sets. 
4.2.1.3  Demon’s DVF QA using contour mapping 
Although the DVF’s were generated by the Pinnacle TPS, a simple QA test was 
performed to validate the usefulness of these DVFs using contour mapping. Figure 8 shows 
the flow diagram of the QA test process. 
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Figure 8: Flow diagram of the pseudo inverse DVF (N %-> 0) and Pinnacle (0 ->N %) QA test process.  The two 
sided arrow means comparing the two contours. 
 
 
The test was conducted on all the patients.  The GTV contoured by the MD on the 
breathing phase 0% (GTV on T0) was mapped to the planning phase N% using the 
PIDVFs.0ToN% (points from N %-> 0), to ensure that the PIDVF was loaded properly to the 
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TPS, a transcript file (terminal window) with the execution commands and details was 
opened during the process, also the PIDVF file resolution was different from the native 
Pinnacle DVF file.  Figure 9 shows an example of how the process was executed from the 
TPS GUI.  The moving image was set to phase 0% (T0) and the fixed image was set to the 
planning image (T1).  In the contour panel, the manual GTVT0 contour was checked as the 
contour to be deformed. 
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Figure 9: Process steps in the TPS deform panel interface to map contours from the moving image (T0) to the 
fixed image (T1).  In the panel, the GTVT0 manual contour was chosen to be mapped to the fixed phase T1. 
 
Figure 10 shows how step 3 in Figure 8 process was executed from the TPS GUI.  
The moving image was set to phase 10% (T1) and the fixed image was set to the planning 
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image (T0).  In the contour panel, the deformed GTVT0 on T1 contour generated by using 
the PIDVF was checked as the contour to be deformed. 
 
 
Figure 10: Process steps in the TPS deform panel interface to map contours from the moving image (T1) to the 
fixed image (T0).  In the panel, the GTVT0 (PIDVF) contour was chosen to be mapped to phase 0%. 
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Figure 11 shows the generated (green) and the manual GTV on phase 0% (blue) on 
transverse, sagittal, and coronal slices for patient P4P100 (same results for the  rest of the 
patients are presented in Appendix II).  The Dice coefficient (DC) [47] [48] [49] (Table 4) 
was also computed to evaluate the percentage volume overlap between the manual GTV0 
and generated contours ((GTV0 (PIDVF N%->0) on phase N% mapped back to phase 0%). 
ܦ݅ܿ݁ ൌ 2ሺܸ1 ∩ ܸ2ሻܸ1 ൅ ܸ2 ൈ 100 (5) 
 
The Dice coefficient has a value of 1.0 when two contours are completely coincident 
and a value of 0.0 when they are entirely disparate, without any overlap.  The mean DC 
and its standard deviation (SD) over all phases for each patient were reported in the last 
two rows of Table 4. The mean DC was ≥ 92% for all patients except the MD-Anderson 
patient, the mean DC was 82%.  The differences in the mean DC can be explained by 
differences in GTV volumes and locations among the patients [49], for example, the MD-
Anderson patient had the smallest tumor volume (2.68 ܿ݉ଷ	ሻ, largest 3D-tumor motion (2.4 
cm), and image artifacts existed in its image data.   
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Figure 11: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P100.  The yellow vectors represent the DVFs (0->N%). 
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Table 4: Dice coefficient values for each generated GTV0 (PIDVF N%->0) on phase N% mapped back to phase 
0% for all patients, the last two rows are the mean DC and its standard deviation over all the breathing phases for each 
patient. 
DC (%) 100 101 102 103 104 105 106 107 110 114 MDA
10 96 95 97 96 92 95 98 96 97 97 82 
20 96 94 97 96 92 95.5 97 96 95 97 82 
30 96 95 97 96 92 95 96.5 95.5 93 96 76 
40 96 95 97 97 92 95 96 95 94 96 77.5 
50 96 94 97 97 92 95 96 94.5 94.5 96 76 
60 97 95.5 97 95 92 95 97 94 95 96 78.5 
70 96 95.5 97 96 91 96 97 95 95 97 85 
80 96 95 97 96 93 95 97.5 96 96 97 90 
90 96 97 97 96.5 93 95 98 96 95 97 90 
avg 96 95 97 96 92 95 97 95 95 96.5 82 
SD ± 0.3 0.9 0.1 0.3 0.6 0.3 0.7 0.75 1 0.5 0.55 
 
 
Please note that the purpose of these generated contours was to test the DVFs, 
none of the deformed generated contours were used in 4D-DVH analysis, the MD manual 
contour on the planning phase was used for planning and will be used for 4D dose 
evaluations. 
Based on the above visual comparisons and the reported DC’s of the compared 
contours for all patients, the (0->N%) DVFs and PIDVFs (N%->0) are suitable for use in the 
dose mapping study.  
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4.2.2 ETM algorithm implementation  
ETM was implemented in our in-house integrated MC calculation system [10] with a 
modified DOSXYZnrc code.  The modified DOSXYZnrc version was called 
etmDOSXYZnrc.  Figure 12 shows how ETM can be run from the TPS.  The ETM simulates 
the particle transport within the source images (breathing phases N%), but scores the 
energy deposition via the DVF at its mapped location in the reference image (end of inhale 
breathing phase).  To get the input mass, CT images (target and source) were converted to 
material mass-density phantom using the CTCREATE program where a 55 material ramp 
was used in the Hounsfield unit (HU)-to-density conversion [39]. 
Figure 12: screen shot of ETM MC dose calculation system integrated into the TPS via a tcl GUI. 
When ETM was first implemented [10] on a phantom case, the mapped dose on the 
reference image was computed by dividing the mapped energy by the mass of the 
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reference image.  Since inconsistencies inherent in current CTs exist between the source 
and the reference image, the mass used in the mapped dose computation should be 
mapped from the source to the reference image to avoid dose mapping error. 
For this thesis work, the energy mass congruent mapping methodology (EMCM) was 
used[11].  Like ETM, the mapped energy deposited was accumulated during the particle 
transport simulation; however, the source masses were mapped from each of the N-
breathing phases to the end of inhale phase.   While the energy and the mass were 
mapped separately for each N-phase mapping, the same DVF (N-phase to 0-phase) was 
used to map the energy and the mass Figure 13.  To avoid any mapping uncertainty due to 
the direction of the DVF, a pseudo inverse DVF was used to map both the energy and the 
mass.  Two important issues should be considered when mapping the mass; (1) any mass 
mapping error can directly translate to a dose mapping error, (2) since the particle energies 
are tracked one by one, to prevent any dose discrepancy caused by the incongruence of 
the two mappings, an in-house C++ program was written to divide the source mass 
phantom into pixel-size/n sub-voxels in X, Y and Z directions.  ݊ ൌ 8 was used in this 
thesis.  The mapped mass was determined by mapping (using the push method) the sub-
voxels’ mass from each of the breathing N phases to the 0% phase.  A 2 ൈ 2 ൈ 2 ݉݉ଷ input 
dose voxel size was used for all MC dose computations and mass phantoms generation.  
The resulting mass sub-voxels’ volume was 0.25 ൈ 0.25 ൈ 0.25	݉݉ଷ which is smaller than 
the CT image resolution (0.97 ൈ 0.97 ൈ 3	݉݉ଷሻ.  Sub-dividing the mapped mass will 
improve the precision of the mass mapping in the mapped dose calculations.  Assuming 
equal volumes of irradiated and reference voxels, the final target voxel density is the 
average of the mapped densities.  
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Figure 13: flow diagram of the EMCM mapping process.  The TPS input dose matrix on each breathing phase 
was converted to per-voxel material and mass matrix using the CTCREATE code.  MC dose was computed on each i-
phase.  The iphase CTCREATE phantoms were simultaneously pushed to T0 using the PID-DVF(i0).  MC energy was 
deposited on T0 using the PID-DVF(i0).  The final mapped dose voxel on T0 was computed by dividing the energy 
deposited on T0 voxel by the mapped voxel mass. 
  
  
For the dose mapping algorithms comparison, I chose EMCM with mass mapping as 
the gold standard algorithm.  This is due to the fact that EMCM directly utilizes the definition 
of dose (section 2.3).  Using EMCM, the energy is mapped event by event in a point-wise 
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fashion which makes the mapping more accurate.  Also EMCM has the ability to map dose 
in regions of discontinuous motion.  By applying mass mapping, ETM will be more accurate 
since both mapped energy and mass will be congruent. 
4.2.3 Dtransform and Pinnacle dose mapping implementation 
Dtransform [13] dose computation was run from the TPS using the in-house GUI.  
Inputs to Dtransform were the MC dose on each of the N breathing phases, both the N-
phases and 0% phase density phantoms and the 0%-N% DVF’s [Figure 14].  The density 
phantoms (source and target) were converted from an EGSPHANT format (CTCREATE 
output) to a VMCPHANT format which is required by the Dtransform code (phantom that 
contains only densities without material numbers or type) using an in-house C++ program.  
Outputs of the Dtransform were the (Nphase to 0 phase) mapped doses.  The mapped 
doses were accumulated on the 0% phase by an automated script and loaded back into the 
TPS. 
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Figure 14: flow diagramof the Dtransform dose mapping process.   The TPS input dose matrix on each breathing 
phase was converted to per-voxel material and mass matrix using the CTCREATE code then was converted to VMC 
phantom format that didn’t contain material information.  MC dose was computed on each i-phase. The T0 voxel was 
divided into 6 tetrahedrons, tetrahedral corners were mapped to N-phase geometry using DVF(0N).  The overlap 
between the transformed voxels and the N-phase voxels was computed.  The mapped dose on T0 was computed by 
dividing the energy and mass in the overlapped voxels. 
 
The Pinnacle dose mapping was performed within the TPS.  Inputs were the MC 
dose on each of the N% breathing phases and the 0%-N% DVF’s Figure 15. 
Dose matrix 
on 
N-Phase(TPS)
Convert Per-voxel 
N-Phase materials 
and 
masses(CTCREATE) 
to VMC-format 
Compute MC 
N-Phase 
dose 
Divide T0 voxel into 
6 tetrahedrons 
Map tetrahedral corners to 
N-phase 
DVF(0N-phase) 
Find overlap 
tetra-voxels 
V(N)∩V(0N) 
DoseMapped=Sum[e(V(N)∩V(0
N))/mass(V(N)∩V(0N))]
 39 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: flow diagram of the Pinnacle dose mapping process.  The interpolated MC dose on each N-Phase 
was mapped to the planning phase using DVF(0N).  The mapped doses were accumulated on T0.	
 
4.2.4 Sub-Voxel dose mapping code implementation 
In this section, I describe the adaptation of Rosu’s Tri-linear interpolation with octant sub-
divisions dose mapping method to other number of sub-voxel divisions.  The implemented 
dose mapping code takes the reference geometry dose matrix and sub-divides each voxel 
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to ݊ଷ sub-voxels.  For each sub-voxel, the voxel centroid is mapped to the irradiated 
geometry and dose at the corresponding point in the irradiated geometry is determined by 
Tri-linear interpolation.  For each reference voxel, the average dose by the ݊ଷ sub-voxels is 
assigned to the dose for the voxel in the reference geometry. 
 
 
 
 
  
  
                                                             
 
                                     
Figure 16: flow diagram of the sub-voxel mapping code.  Each reference voxel is divided to ࢔૜ sub-voxels.  Each 
reference sub-voxel point coordinate is computed and mapped by the DVF to locate its corresponding location in the 
irradiated geometry.  The sub-voxel dose at the irradiated point is computed by Tri-linear interpolation.   The average dose 
by ࢔૜ the sub-voxels is assigned to the dose for the voxel in the reference geometry.  
4.3 Determining target volume with maximum DME potential 
In this section, I investigate the effect of choosing a planning target on dose mapping 
methods.  The first part of this section determines which margin around the tumor is 
expected to result in large DME.  In the second part, the determined margin is used to 
generate treatment plans on the reference phase for each patient, then 4D cumulative dose 
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estimates are computed using EMCM, tri-linear (with sub-voxels), Pinnacle, and Dtransform 
and compared. 
4.3.1 Motivation 
DME occurs when the DVF used for mapping the dose is not accurate, density and 
dose gradients exist in the irradiated geometry (section 2.3 ).  High dose gradients are 
expected on the target borders where there is a sharp fall off of the dose.  Density 
gradients on the target border depend on how the target is defined and what structures are 
surrounding it.  If the density gradient on the GTV, CTV, and PTV borders was computed, 
the target that has the highest density gradient on its border would provide a good study 
case for potential DME analysis.     
4.3.2   Method 
The tumor, CTV and PTV mask files were extracted from the TPS system using a 
Pinnacle script.  The script returns a binary mask (1 if inside the contour, 0 if outside) 
generated from an ROI.  'Inside' was defined as a voxel whose center is within the polygon 
defined by the contour on a particular slice. A mask was applied (using in-house C++ 
algorithm) on the generated contour files to determine the edge voxels around each 
contour Figure 17.  The generated mask files had the same file size as the original contour 
files with values of 1 and 0.  Values of one represented the edge voxels, whereas values of 
zero represented voxels everywhere else in the contour file.  The tumor, CTV, and PTV 
edge voxels mask files were imported into the MATLAB workspace and new files that 
contain only the voxels with values of one were generated using the “find” indices equal to 
one command.   
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Figure 17: flow diagram of the code that computes the ROI edge voxels mask. 
To evaluate the image gradient (a surrogate for mass gradient) on the edge voxels 
of each of the tumor, CTV, and PTV contours, the irradiated CT image was imported into 
MATLAB and its gradient was computed.  The image gradient was computed in the X, Y, 
and Z directions using the MATLAB gradient function.  The 3D image gradient magnitude 
was determined by computing the square root of the sum of the squares of each image 
gradient vector in the X, Y, and Z directions. 
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Once the 3D image gradient was computed, the image gradient on each of the 
tumor, CTV, and PTV edge voxels was found by returning the values of the 3D image 
gradient at the specified edge voxel indices (tumor, CTV, and PTV voxels with values of 
one).  Histograms of the generated files were then computed.  From the histograms, 
complementary cumulative distribution functions (CCDF which is 1-CDF) of the frequency 
of the 3D edge voxel image gradients were generated and plotted.  Since DME is 
proportional to the mass gradient γ, the CCDF curve, which has the highest density 
gradient, will determine the planning target that might result in high DME.  
4.3.2.1  Findings 
PTV, CTV, and tumor CCDF’s versus breathing phase 50% CT image gradients on 
the edge voxels were plotted for each of the 11 lung patients [Appendix II].  To present the 
results for all the 11 patients, the 3D image gradients on the edge voxels were sampled 
from each patient CCDF curve at the 50% CCDF values [Figure 18].  Please note that 
graphs were only generated for breathing phase 50% (end of exhalation) since this phase 
is the opposite phase for the breathing phase 0% (end of inhalation) and is expected to 
have higher average lung tissue density than the rest of the breathing phases[50-52]. 
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Figure 18: 3D magnitude of the image gradient on edge voxels of the PTV (black triangle), CTV (red square), 
and tumor (blue circle) on breathing phase 50% for the 11 patients. 
4.3.2.2  Analysis 
The above graphs show that for the various target volumes considered on the 50% 
CT breathing phase, the image gradient is highest on the tumor (GTV) edges  (blue curve) 
and lowest on the edges of the PTV (black curve).  For most patients, the CTV curve (red) 
falls between the tumor and PTV curves.  Since dose distributions aim to conform to the 
target volume, hypothetically, plans based on the tumor (GTV) result in the highest target 
DME, hence are used for other studies in this dissertation to accentuate the differences. 
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4.3.3 Comparison of dose-mapping algorithms for 4D GTV-based plans 
for ૛ ൈ ૛ ൈ ૛	࢓࢓૜ dose grid size 
 
4.3.3.1 Purpose 
To compare dose-mapping algorithms using the GTV as the planning target for 4D-
dose calculations. 
4.3.3.2  Method 
For each patient, an IMRT treatment plan was generated on phase 0 % directly on 
the tumor.  IMRT planning optimizing criteria were the same as discussed in section 4.1.2 
with no PRVs created on the spinal cord or esophagus.  The beams were copied to the rest 
of the breathing phases (10 – 90 %) and the MC dose was computed on each breathing 
phase using 2×2×2 ݉݉ଷdose grid size.  The MC dose from each breathing phase was 
mapped back and accumulated on the reference phase using EMCM, Pinnacle, Tri-linear 
with Sub-voxeling n= 1, 2, and 3, and Dtransform dose mapping methods. 
Comparison metrics on the reference phase were derived from dose volume 
histogram indices such as tumor (D98 and D50), cord (D1), esophagus (V55), mean lung 
dose, lung (V20), normal tissue (V66), and heart (V40).  Dose and volume indices were 
also reported based on the differences observed in the 4D-DVHs.  The cutoffs for potential 
clinically relevant differences were >2% volume variations for the specified parameters 
DVH metrics and >1 Gy differences of the spinal cord D1% >1 Gy [53].  A paired two tailed 
statistic test was performed on D98, D50, and MLD to determine if the difference among 
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the dose mapping methods was statistically significant (p-value < 0.05).  Voxel by voxel 
total dose difference statistics were also reported to identify differences that did not show 
up in the DVHs. 
4.3.3.3  Results and analysis 
For each patient, Table 14 [Appendix IV] displays the 4D-DVHs of the accumulated 
dose on the reference phase.  For all of the dose mapping methods for the tumor, lung, 
esophagus, heart, cord, and normal tissue on the left.  On the right is the difference in DVH 
indices among the dose mapping methods with respect to EMCM: Pinnacle-EMCM (Pin), 
Tri-linear with number of voxels 1-EMCM (N1), Tri-linear with number of voxels 2-EMCM 
(N2), Tri-linear with number of voxels 3-EMCM (N3), and Dtransform-EMCM (Dtran).  D98, 
D50, MLD, and cord D1 are reported in cGy.  Percentage differences in volume indices 
were also reported for lung, esophagus, and normal tissue.   
  The lung V20Gy DME (%) and MLD DME (cGy) for all the dose mapping 
algorithms were not clinically significant for all patients [Figure 19 and Figure 20]. 
For patient P4P101, since the normal tissue volume did not get 66 Gy, V10 was 
chosen arbitrarily as a comparison metric.  For Pinnacle, Dtransform, and Tri-linear with 
sub-voxels 1, 2, and 3, the normal tissue difference V10 with respect to EMCM is > 2%, 
which is significant.  No significant differences in dose and volume indices were observed 
for patient P4P102 except for heart V10 (3%).  These differences are attributed to the 
inherent difference between EMCM and the rest of the methods. 
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Figure 19: V20Gy DME (%) for Pinnacle (red circle), Tri-linear with nSub-voxels=3(blue square), and Dtransform 
(black triangle) for the 11 patients. 
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Figure 20: Lung MLD DME (cGy) for Pinnacle (red circle), Tri-linear with nSub-voxels=3 (blue square), and 
Dtransform (black triangle) for the 11 patients. 
Tumor D98 differences of > 1Gy were observed for all the dose mapping methods 
with respect to EMCM for patient P4P103 [Figure 21:P4]. [Figure 22] shows the 4D-dose y-
profiles for EMCM, Dtransform and their difference.  The two profiles differ by 2 Gy in the 
sharp dose fall off region.  [Figure 23], displays the 4D-dose y-profiles for EMCM, Pinnacle 
and their difference, the two profiles differ also in the penumbra region by ~ -10%. Although 
the difference is in the penumbra region, when OARs were located in the penumbra region, 
the DME impacts the mapped OAR’s accuracy.  The difference in EMCM and Tri-linear with 
n=3 4D-dose y-profiles was minimal [Figure 24].   
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Figure 21: D98% DME (cGy) for Pinnacle (red circle), Tri-linear with nSub-voxels=3(blue square), and 
Dtransform (black triangle) for the 11 patients. 
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Figure 22: P4P103 4D dose y-profiles for EMCM (green), Dtransform (green) and their difference in red.  The 
profiles show the two methods differ by 2 Gy in the sharp dose fall off region. 
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Figure 23: P4P103 4D dose y-profiles for EMCM (green), Pinnacle (green) and their difference in red.  The 
profiles show the two methods differ by ~ -10% % in the penumbra region. 
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Figure 24:  P4P103 4D dose y-profiles for EMCM (green), Tri-linear with subvoxels n =3 (green) and their 
difference in red.  No large differences are observed between the two methods. 
 
There were significant differences in D98, D50 between Pinnacle and EMCM (1.2 
1.14 Gy) for the MD-Anderson patient [Figure 21:P11]. Section 4.3.4 provides deep 
analysis on these reported results for the MD-Anderson patient.  Also, difference of 3% in 
esophagus V10 for Pinnacle with respect to ETM was observed.  There were no significant 
differences in cord D1, normal tissue, and heart V10.   
To investigate any significant 4D dose differences that don’t show in the 4D-DVHs, 
DME statistics over the whole dose matrix are reported in Table 5.  
    
 53 
Table 5. Total 4D absolute dose difference statistics (Gy) for dose mapping methods with respect to EMCM for 
the 11 patients.  
 
Patient #  Pinnacle‐EMCM  Dtrans‐EMCM  Nsub1‐EMCM  Nsub2‐EMCM  Nsub3‐EMCM 
  max  Avg  SD  max  avg  SD  max  avg  SD  max  avg  SD  max  avg  SD 
100  24.72  0.22  0.67  21.5  0.21  0.6  24.72  0.19  0.64  24.72  0.19  0.64  24.72  0.19  0.64 
101  24.58  0.19  0.73  24.43  0.19  0.7  24.25  0.185  0.72  24.2  0.185  0.72  24.21  0.185  0.72 
102  23.2  0.38  0.82  27.98  0.42  0.89  28.1  0.4  0.89  28  0.4  0.89  28  0.4  0.89 
103  22.4  0.21  0.53  22.58  0.15  0.41  24.18  0.17  0.48  23.74  0.17  0.47  23.67  0.17  0.47 
104  40.97   0.43  0.89  42.45  0.32  0.78  40.93  0.31  0.75  40.86  0.32  0.75  40.83  0.32  0.75 
105  28.86  0.14  0.4  27.15  0.11  0.36  29.23  0.11  0.39  29.03  0.11  0.34  29  0.11  0.36 
106  17.75  0.2  0.47  22.59  0.16  0.39  19.2  0.15  0.39  18.54  0.15  0.39  18.5  0.15  0.39 
107  21.72  0.08  0.32  21.34  0.05  0.2  21.97  0.05  0.2  21.83  0.06  0.21  21.79  0.056  0.21 
110  18.34  0.12  0.37  18.54  0.08  0.28  18.7  0.08  0.29  18.5  0.085  0.29  18.5  0.086  0.29 
114  28.7  0.24  0.59  27.66  0.22  0.57  30.71  0.26  0.63  30  0.26  0.61  30  0.26  0.61 
MDA  21.57  0.26  0.96  20.91  0.04  0.17  21.49  0.04  0.15  21.56  0.04  0.15  21.56  0.04  0.16 
 
The average absolute DME for all patients was < 1 Gy [Figure 25], which is not 
clinically significant; however the maximum absolute DME for all patients ranged from 18 to 
41 Gy.  If the maximum DME occurs in the tumor or OARs it will have an impact on the 
dose mapping accuracy, for example, maximum differences >20 Gy in DME sometimes in 
relevant normal tissue, such as airways in patient P4P101 is important for toxicity.  To 
investigate the location of the maximum DME on patient anatomy, total 4D dose difference 
files were loaded back to the TPS.  Figure 73-Figure 83 in Appendix V show the location of 
the maximum absolute DME for all patients for Pinnacle, Tri-linear with n=3, and 
Dtransform.  
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Figure 25: average and SD of the absolute 4D-dose difference DME (Gy) for Pinnacle (blue circle), Dtransform 
(red square), and Tri-linear with n=3 for the 11 patients. 
 
None of the maximum absolute DME points (plotted with a symbol with a 2 cm 
diameter) occur in the tumor for all the patients. The regular DME statistics table and the 
location of the maximum DME point are also included in Appendix V [Table 11, Figure 84-
Figure 94].  
To check if the difference in D98, D50, lung V20 and MLD is statistically significant 
for all dose mapping methods with respect to EMCM, a student two tailed t-test was done. 
P-values were reported in Table 6, a p-value < 0.05 is considered statistically significant.  
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P-values for the tumor D98 and D50 showed no significance, this is expected since dose in 
target is uniform.  Lung V20 and MLD p-values were significant for all the dose mapping 
algorithms since dose is non-uniform. 
   
Table 6: P values for D98, D50, Lung V20 and MLD for all dose mapping methods with respect to EMCM. 
Pvalue  Pin&EMCM  Nsub1&EMCM  Nsub2&EMCM  Nsub3&EMCM  Dtrans&EMCM 
Tumor D98  0.39  0.24  0.23  0.23  0.75 
Tumor D50  0.33  0.09  0.08  0.07  0.4 
Lung V20  0.01  0.005  0.005  0.005  0.004 
MLD  0.003  0.001  0.001  0.001  0.002 
4.3.4 Analysis of Pinnacle DME for the MD-Anderson patient: 
The 4D-DVHs’ graph for the MD-Anderson showed that the difference in the 4D-
DVH among Pinnacle, Dtransform, and tri-linear dose mapping algorithms was significant.  
This was an un-expected result since, especially considering tri-linear and Pinnacle which 
are both point-based dose mapping algorithms; ideally they should yield similar results.  To 
find out the reason behind the difference between Pinnacle and Tri-linear algorithms, 
several tests were conducted, starting with looking at the 4D-dose distribution of the two 
algorithms compared to each other and to the source dose before mapping.  The test was 
done using the two extreme phases (0% and 50%).  The dose was mapped from phase 
50% to phase 0% using both algorithms.  Figure 26 shows the sagittal (a) and coronal (b) 
views of the mapped dose distribution, Tri-linear (with n =1) on the left panel and Pinnacle 
on the right panel. 
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Figure 26: sagittal (a) and coronal (b) views of the mapped dose from phase 50% to phase 0%, Tri-linear was 
displayed on the lest panel and Pinnacle on the right. 
Figure 27 compares the mapped dose (left panel) Tri-linear (a) and Pinnacle (b) to 
the phase 50% source dose (right panel).  Please note that, the mapped dose does not 
cover the tumor (left panel) since it is estimated from the irradiated dose on phase 50%.  
On phase 50 % the tumor moves outside the treatment beams (right panel). 
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Figure 27: coronal views of the mapped dose on the left panel and source dose on the right panel, Tri-linear (a) 
and Pinnacle (b). 
To further analyze the differences, the same mapping test was repeated but using 
an in-house zero DVF.  Mapping the source dose with a zero DVF is one of the basic tests 
that can be performed to check the accuracy of a dose mapping algorithm.  With a zero 
DVF the output mapped dose must be identical to the source dose since there is no dose 
mapping done.  
The DVF 0% to 50% was read into Matlab and its values were set to 0.  The DVF 
then was exported to the patient directory and used in the mapping of the source dose 
(phase 50%) to the target phase (phase 0%). The Tri-linear algorithm produced a zero 
dose difference with the source dose however the Pinnacle algorithm did not [Figure 28].   
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Figure 28: coronal view of the difference between the irradiated dose on phase 50% and the mapped dose with 
zero DVF for Tri-linear (N=1) on the left panel and Pinnacle on the right panel. 
 
The above results were shared with Philips Company.  Philips verified that their non- 
commercial algorithm does not use Tri-linear dose interpolation but nearest neighbor 
interpolation which might explain the different results.  Upon receiving a new version of 
Pinnacle (non-commercial) that contains a dose mapping algorithm with Tri-linear 
interpolation, the test was repeated with zero DVF and with the patient DVF.  With the zero 
DVF test, Pinnacle with Tri-linear produced ~ a zero dose difference with the source dose 
(with in round off error) [Figure 29]. 
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Figure 29: coronal view of the difference between the irradiated dose on phase 50% and the mapped dose with 
zero DVF for Tri-linear (n=1) on the left panel and Pinnacle with Tri-linear on the right panel. 
With the real (patient) DVF the Pinnacle with Tri-linear interpolation algorithm 
showed a little different result over the Pinnacle with nearest interpolation algorithm. Figure 
30 shows the accumulated Pinnacle dose before (solid line) and after (dashed line) the 
dose interpolation algorithm correction compared to the Tri-linear in-house code (left solid 
line).   
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Figure 30: 4D-DVH plot showing the accumulated Pinnacle dose before (solid line) and after (dashed line) the 
dose interpolation algorithm correction compared to the Tri-linear in-house code (left solid line). 
For the above test case,  the change in the tri-linear-based Pinnacle dose mapping 
algorithm was not clinically significant (mean mapped dose difference of 4.3 cGy between 
Pinnacle with nearest and Pinnacle with Tri-linear) to reduce the big difference that was 
observed between Pinnacle and the in-house Tri-linear code,  the observed differences are 
characteristic of a process implementation difference which could result from a difference in 
the DVF readers used for Pinnacle and the in-house code, or from some aspect of not 
using translation/rotation parameters during DVFs generation ,  this was only observed for 
this patient who had large tumor motion (2.4 cm).   
4.3.5 Conclusion: 
In section 4.3.3, comparison of dose mapping algorithms was done on 11 lung 
cancer patients.  Comparison metrics included 4D-DVH’s indices, voxel by voxel total dose 
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difference statistics, MLD, maximum DME point location on anatomy, dose profiles in the y-
axis and statistical t-test. 
Tumor 4D-DVH D98 was not significant for all the patients except P4P103 for all the 
methods, and the MD-Anderson patient (1.2 Gy for Pinnacle), for the P4P103 patient, dose 
profiles in the y-axis showed that DME occurs in the penumbra region.  Voxel by voxel total 
dose difference statistics showed no clinical significance for the average DME.  Although 
the maximum DME was clinically significant for all the patients, when loaded back to the 
TPS and visualized on patients anatomy, the DME was not located in the tumor or the 
evaluated OARs.  In all patient cases there was no clinical effect on the MLD.  Statistically, 
lung V20 and MLD showed significance for the entire dose mapping algorithms. 
For the MD-Anderson patient which had considerable amount of 3D tumor motion 
(>10 mm ), Pinnacle dose mapping code differed significantly for D98 from all the other 
codes, this might be attributed to the difference in DVF Pinnacle and in-house readers.   
Although I have chosen DME of 1 Gy to be the level of clinically significant 
difference, it remains a Radiation Oncologist’s decision whether to accept this level or not.   
In conclusion, the results are patient and tumor motion specific.  Please note that, as 
discussed in Section 0, choosing a zero margin around the tumor might yield to the highest 
DME as compared to generating plans on the CTV or the PTV, so the results shown above 
models dose mapping under non-clinical conditions designed to maximize the DME.  The 
DME should be less when plans are generated when the effect of tumor motion is taken 
care by using the ITV and ITV-PTV margin. 
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4.4 Effect of using the PTV as a planning target on DME 
4.4.1 Motivation 
Section 4.3.2.1 results showed that the density gradients around the tumor were 
higher than the density gradients around the PTV [Figure 62-Figure 72].  For plans that are 
generated on the tumor, the DME might be higher than the DME when plans are generated 
on the PTV; however, using the tumor as a planning target is not currently an acceptable 
clinical treatment method due to several reasons, such as the movement of the tumor 
outside of the radiation beams during the treatment delivery, the probability of the presence 
of more disease cells around the defined tumor structure, patient setup errors, etc... To 
simulate a more clinically realistic scenario and to validate the results in section 4.3.2.1 , in 
this section, we chose two patients to study the effect of using the PTV as the planning 
target on the DME.  Similar to the rest of the patients, those patients had high density 
gradients around the tumor and their 4D-tumor-plans showed OARs DME.  
The treatment plans’ designs were the same procedure as in Section 4.1.2: the PTV 
was created on breathing phase 0% (the planning phase) by adding an isotropic 5 mm 
margin to the ITV.  Indices of comparison were the same as in section 4.3.3.2. 
4.4.2 Results 
Table 7 shows the 4D-DVHs of the accumulated dose on the reference phase for the 
tumor based plan on the left, and the PTV based plan on the right. Please note that the 
PTV plan was generated on the PRVs of the cord and the esophagus while the tumor plan 
was generated with no PRVs.  To make the comparison valid between the two plans, the 
DVHs of the OARs with no PRVs are displayed. Visually, it can be seen that the difference 
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among the dose mapping methods for the heart, esophagus, lungs-tumor and normal 
tissue was less when the PTV plan was used.  To quantify these results, tumor D98% and 
OAR DVH indices were reported and compared. 
Table 7: 4D-DVHs of the accumulated dose on the reference phase for each patient on the left for the tumor 
based plan and on the right for the PTV plan. 
 
  
 
Table 8 and Table 9 compare the DME in the DVH volume indices for the tumor, 
heart, lungs, normal tissue, and esophagus for the tumor based plan and PTV based plan 
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for patients P4P101 and P4P102.  Please note that the reported values were for the OARs 
that visually showed a DVH difference between the tumor based plan and PTV based plan.  
In Table 8, the results for the Dtransform, tri-linear sub-voxeling (with n=1), and 
Pinnacle dose mapping codes show that the DME was reduced by 2.1%, 2.6%, and 2.6% 
for the normal tissue V10 when the PTV plan was used for planning.  There was no clinical 
significant effect on the DME for the rest of the organs between the tumor and PTV based 
plan. 
Table 8: P4P101 tumor and OAR volume indices for Dtransform, rcfnSub1, and Pinnacle DME for the tumor 
based plan and the PTV plan. 
 Tumor 
ܦଽ଼%(cGy) 
Heart 
ଵܸ଴ீ௬(%) 
Lungs-tumor 
ଶܸ଴ீ௬(%) 
Normal tissue 
ଵܸ଴ீ௬(%) 
P4P101 Tumor PTV Tumor PTV Tumor PTV Tumor PTV 
Dtransform 13 24 2 1.6 0.7 0.25 2.6 0.5 
rcfnSub1 10 14 2 0.7 0.7 0.19 3 0.4 
Pinnacle 11 8 2 0.7 0.7 0.19 3 0.4 
 
In Table 9, the results for the Dtransform, tri-linear sub-voxeling (with n=1), and Pinnacle 
dose mapping codes show that the DME for the heart V10 was reduced by 2.6%, 2.85%, 
and 2.65% when the PTV plan was used for planning. 
Table 9: P4P102 tumor and OAR volume indices for Dtransform, rcfnSub1, and Pinnacle DME for the tumor 
based plan and the PTV plan. 
 Tumor 
ܦଽ଼%(cGy) 
 
Esophagus  
ସܸହீ௬ሺ%ሻ 
 
Heart  
ଵܸ଴ீ௬ሺ%ሻ 
Lungs-tumor  
ଶܸ଴ீ௬ሺ%ሻ 
Normal tissue  
ଶܸ଴ீ௬(%) 
P4P102 Tumor PTV Tumor PTV Tumor PTV Tumor PTV Tumor PTV 
Dtransform 37 1 2.5 0 2.8 0.15 0 0 1.5 0 
rcfnSub1 36.5 2.5 2.5 0 3 0.15 0 0 1.5 0 
Pinnacle 44 20 2.4 0 3 0.4 0.02 0.02 2 0.3 
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4.4.3 Conclusion 
The above results for the two patients showed that the DME for the OARs heart, 
lungs (P4P101), normal tissue and esophagus (P4P102) was reduced when the PTV was 
used as a planning target. These reductions were clinically significant (>2%) for P4P102 
esophagus V45, heart V10, and P4P101 normal tissue V10. 
4.5  Comparison of dose mapping algorithm at 4×4×4 ࢓࢓૜  
A lot of research work has been done on choosing an optimal dose grid size for dose 
computation [54] [55] [56].  For planning purposes on a static geometry, sufficient dose grid 
resolution is the resolution at which dose interpolation is a sufficient approximation of dose 
at all points in the geometry [57].  Dempsey has found that at dose grid size < 2.5 mm 
point-based dose computation algorithms converge with volume-based dose computation 
algorithms and an isotropic dose grid with <2.5 mm is sufficient to prevent dose errors 
larger than one percent.  By extension, for deformable dose mapping, sufficient resolution 
is that at which interpolation introduces insignificant errors. 
In this section, I study the effect of changing the dose grid size to 4 mm on dose 
mapping error for the 11 patients.  
4.5.1  Method 
The same treatment plans used in Section 4.3.3 were used for this sub-aim, except 
the dose grid size was changed to 4 mm by the following procedures for each patient. 
To ensure consistency with the 2x2x2	݉݉ଷ results and save computation time, the 
4x4x4 ݉݉ଷ MC dose results were created by re-binning (merging) the 2x2x2 ݉݉ଷ results.  
This was accomplished as follows: (1) The 2 mm per phase MC doses were multiplied by 
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their respective 2 mm per phase mass files (generated at the time the EMCM code was run 
in 4.3.3) to obtain the 2 mm per phase energy files. (2) For each energy file obtained from 
step (1), 2 mm energy voxels were merged to form the energy file at 4 mm resolution.  (3) 
The same procedure was done on the mass files to obtain mass files at the 4 mm 
resolution.  The 4 mm per phase irradiated doses were generated by dividing the energy 
files from (2) by the mass files from (3). 
Once the 4 mm per phase MC doses were obtained, they were loaded into Pinnacle.  
Dtransform, Tri-linear (with sub-voxeling 1, 2, 3), and Pinnacle dose mapping codes were 
run to generate the 4D accumulated doses on the reference phase.  Instead, the next 
paragraph explains the procedure by which the EMCM 4 mm accumulated dose was 
obtained for each patient plan.   The 4D EMCM accumulated 4 mm per phase doses were 
generated by dividing the merged 2 mm per phase mapped energy voxels by the merged 
2mm per phase mapped mass voxels. Total 4D 4 mm EMCM doses accumulated on the 
reference phase were generated by adding the per phase accumulated doses.  The EMCM 
mapped dose at 2x2x2	݉݉ଷ	was considered the gold standard algorithm for comparison.  
4D dose comparison metrics were the same used in Section 4.3.3 .  Like the analysis that 
were done on the results in previous sections, any differences between DVH volume 
indices that are > 2% and > 1 Gy for DVH dose indices were considered clinically 
significant.  
4.5.2  Results  
Table 10 shows the 4 ൈ 4 ൈ 4	݉݉ଷand 	2	 ൈ 2 ൈ 2	݉݉ଷ4D-DVHs for patient P4P100 (on the 
left column), on the right are tables for each patient with data that corresponds to the 
absolute difference in OAR 4D-DVH volume indices with respect to EMCM 2	 ൈ 2 ൈ 2	݉݉ଷ.  
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The data under the 4 ൈ 4 ൈ 4	݉݉ଷ header represents the absolute difference in OAR 4D-
DVH indices at 4 ൈ 4 ൈ 4	݉݉ଷ for EMCM, N1(Trilinear), N3(Trilinear with sub-voxeling n=3), 
and Pin (Pinnacle) with respect to EMCM 2	 ൈ 2 ൈ 2	݉݉ଷ .  The data under the 2	 ൈ 2 ൈ
2	݉݉ଷ header represents the absolute difference in OAR 4D-DVH indices for N1, N3, and 
Pinnacle at  2	 ൈ 2 ൈ 2	݉݉ଷ with respect to EMCM 2	 ൈ 2 ൈ 2	݉݉ଷ.  Similar data for the rest 
of the patients are presented in Appendix VI [Table 15].  Table 11 lists the tumor D98 
absolute differences for both dose grid sizes with respect to EMCM 2	 ൈ 2 ൈ 2	݉݉ଷ. 
Table 10: 4D-DVHs of the accumulated dose on the reference phase for patient P4P100 using 4 ൈ 4 ൈ 4	݉݉ଷ  
and 2 ൈ 2 ൈ 2	݉݉ଷ on the left.  On the right are tables for each patient with data that corresponds to the absolute 
difference in OAR 4D-DVH volume indices with respect to EMCM 2 ×2 ×2  ݉݉ଷ for both dose grid sizes for EMCM, N1, 
N3, and Pinnacle dose mapping algorithms.  
 
P4P100  4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ହܸହீ௬
1.2  1.4  1.5  1.3  0.11  0.18  0.16 
Hear
t 
ସܸ଴ீ௬
0.4  0.3  0.3  0.3  0.1  0.1  0.1 
Lung
(%) 
ଶܸ଴ீ௬
0.04  0.36  0.33  0.34  0.36  0.35  0.35 
Cord
(cGy) 
ܦଵ%  
13  58  67  94  2.5  0  16 
N.T(
%) 
ଶܸ଴ீ௬
0.03  1  1  1  1  1  1 
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For all OARs for patients P4P100, P4P103, P4P104, P4P106, P4P110, P4P114, 
and the MD-Anderson patient, the DMEs were not clinically significant for the listed DIM 
methods for both dose grid sizes. 
For Patient P4P102, the DMEs at 4	 ൈ 4 ൈ 4	݉݉ଷ for the cord ܦଵ% and normal tissue 
ଶܸ଴ீ௬ were clinically significant and were reduced to non-clinically significant values when a 
dose grid of 2	 ൈ 2 ൈ 2	݉݉ଷwas used. The esophagus ଷܸହீ௬ EMCM DME was clinically 
significant; there might be two reasons for the DIM DMEs at  4	 ൈ 4 ൈ 4	݉݉ଷ , one of them 
is the 4D-dose interpolation error inherited in the DIM methods and the difference in the 
planned dose DVHs at both dose grid sizes which suggests that the 4 mm dose grid is 
insufficient resolution for treatment planning dose calculation [Figure 31].  The difference 
between the original planned doses at both dose grid sizes for the esophagus might have 
been propagated to cause a clinically significant error for the EMCM DME.  Similar 
interpretation could be applied on patient P4P105 cord	ܦଵ% DME [Figure 32], P4P101 
normal tissue  ଵܸ଴ீ௬ [Figure 33], P4P107 tumor ܦଽ଼% , cord	ܦଵ%, and esophagus ଶܸହீ௬ 
[Figure 34], and the MD-Anderson patient tumor ܦଽ଼% . 
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Figure 31:  DVHs of (1/10)*planned dose on phase 0% for both dose grid sizes for P4P102. 
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Figure 32: DVHs of (1/10)*planned dose on phase 0% for both dose grid sizes for P4P105. 
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Figure 33: DVHs of (1/10)*planned dose on phase 0% for both dose grid sizes for P4P101. 
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Figure 34: DVHs of (1/10)*planned dose on phase 0% for both dose grid sizes for P4P107. 
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Figure 35: DVHs of (1/10)*planned dose on phase 0% for both dose grid sizes for MD-Anderson. 
 
To further analyze the results, [Table 11] lists the tumor 4D-D98 (cGy) Trilinear N1, 
N3, and Pinnacle absolute differences with respect to EMCM for both dose grid sizes. For 
patients P4P100, P4P102, P4P106, and P4P110 the DMEs were not clinically significant 
between the two dose grid sizes.  For the same dose mapping method EMCM, the DME 
was clinically significant between the two dose grid sizes for patients P4P101, P4P103, and 
P4P114. For these patients, the DVH plots of the original planned dose at both dose grid 
sizes did not show any large differences for the tumor ܦଽ଼% Figure 33, Figure 36, and 
Figure 37, thus this EMCM DME might be due to the resampling of the 4D-EMCM 4mm 
from the 4D-EMCM 2mm. 
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Table 11: Tumor 4D-D98 (cGy) Trilinear (N=1,3), Pinnacle, and EMCM absolute differences with respect to 
EMCM at 2x2x2 mm^3  for all the patients for both dose grid sizes.   
Tumor D98 
in cGy 
  
4 ൈ 4 ൈ 4	݉݉ଷ 
 
   
2 ൈ 2 ൈ 2	݉݉ଷ 
 
 ETM N1 N3 Pin N1 N3 Pin 
P4P100 24 19 39 15 4 3 12 
P4P101 166 51 84 65 10 5 11 
P4P102 15 13 19 9 37 37 44 
P4P103 193 16 51 196 229 229 414 
P4P104 51 83 100 100 15 20 35 
P4P105 30 68 101 98 15 24 54 
P4P106 11 1 9 15 11 12 11 
P4P107 190 242 270 230 33 39 23 
P4P110 0.35 17 38 58 5 9 36 
P4P114 
 119 51 35 30 37 40 61 
MD-And 202 286 284 294 42 33 118 
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Figure 36: DVHs of (1/10)*planned dose on phase 0% for both dose grid sizes for P4P103. 
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Figure 37: DVHs of (1/10)*planned dose on phase 0% for both dose grid sizes for P4P114. 
 
Table 12 shows the DME RMS at both dose grid sizes for all patients for tumor 	
ܦଽ଼% , lung ଶܸ଴ீ௬ , and cord ܦଵ%. The DMEs RMS were reduced at 2 ൈ 2 ൈ 2	݉݉ଷ for the tumor, 
cord, and lung ଶܸ଴ீ௬. 
Table 12: DMEs RMS for all patients at the two dose grid sizes for the tumor, lung, and cord. 
																																				4 ൈ 4 ൈ 4	݉݉ଷ 
 
2 ൈ 2 ൈ 2 ݉݉ଷ 
 
RMS  N1  N3  Pin  N1  N3  Pin 
Tumor 
ܦଽ଼%  120  131  137  73  73  134 
Lung(%) 
ଶܸ଴ீ௬   0.5  0.5  0.5  0.43  0.43  0.4 
Cord(cGy) 
ܦଵ%  
106  109  108  17  18  35 
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 Appendix VI [Table 16-Table 17] contains more 4 mm dose grid 4D data results for 
OARs and tumor for all dose mapping algorithms compared to EMCM. 
 
 
4.5.3 Conclusion 
The above results showed that, as the dose grid size becomes smaller, the RMS for 
the DME for DIM over all the patients becomes smaller for the tumor 4D-ܦଽ଼%, lung ଶܸ଴ீ௬ , 
and cord ܦଵ% .   The clinical effect of changing the dose grid size from 4 mm to 2 mm on 
dose mapping was small for OARs and was patient specific. 
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5 A Distance to Dose Difference tool for estimating the Required 
Spatial Accuracy of a Displacement Vector Field  
As mentioned in previous chapters, accuracy of dose mapping depends on the 
accuracy of the DVF used in the mapping process and on the local dose gradient in the 
irradiated geometry.  Some DVF errors are inconsequential.  For example, if a registration 
DVF error occurs in a uniform dose region [Figure 38a], then the resultant dose error is 
small.  Conversely, if a registration error occurs in a high dose gradient, such as in the 
penumbra region, [Figure 38b] then resultant dose error can be large. 
  
Figure 38: Illustration of the effect of the displacement vector field (DVF) errors on dose mapping errors.  On 
each panel, the green arrows are possible displacement vectors for mapping information from the irradiated image to the 
reference image.  The red arrow represents the DVF error.  In (a), the error occurs in a uniform dose region; hence the 
dose mapping error is minimal.  In (b), the error occurs in a dose gradient region, resulting in a large dose mapping error.   
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One can exploit this relationship between DVF accuracy and dose mapping 
accuracy to determine how large of an DVF error could be tolerated before it could 
introduce a given dose error.  For example, if the desired dose mapping accuracy is 2% of 
the local dose, then DVF errors are relevant only if the dose at an incorrectly mapped point 
is >2% different from the dose at the “correctly” mapped dose point.  This suggests that a 
metric which provides an upper bound of allowable DVF uncertainty can be developed 
based upon a distance to difference (DTD) analysis, where the distance to a dose 
difference threshold in the irradiated geometry is evaluated. 
The DTD concept is unique in that it does not require knowledge of the DVF.  
Instead, DTD indicates how large a DVF error can be before the DVF error could introduce 
a pre-determined maximum tolerable dose mapping error.  The DTD threshold is adaptable 
based on the desired evaluation; DTD can be for a given percentage of the local dose, 
given percentage of maximum dose, for any arbitrary absolute dose difference, or even to 
an absolute dose level. 
This chapter introduces the DTD concept which was published as a part of this 
dissertation work [58] (See Appendix I), demonstrates its use for mapping dose between 
two phases of a 4D lung plan, and compares the DTD with a method based on the gradient 
of the dose distribution. 
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5.1 Method and materials 
5.1.1  DTD algorithm 
Although a computer algorithm could be written that directly computed DTD, the 
DTD algorithm [Figure 39] used in this work is developed using a technique similar to that 
used for distance to agreement (DTA) analysis.   
DTA utilizes two dose distributions, A and B, on a common coordinate system which 
are to be compared.  For each dose value at a point in distribution A, the DTA is the 
shortest distance that must be traversed in B to have an equivalent dose value.  This 
concept can be extended to a DTD concept.  DTD utilizes a single dose distribution as 
input since the desire is to determine the minimum distance one must traverse in this dose 
distribution to observe a dose difference greater than the tolerance.  For example, if the 
desired dose accuracy is n=2% of the local dose, then beginning with dose distribution A, a 
dose distribution B+ is created by multiplying the dose values in A by (1+n/100)=1.02 .  The 
DTA at each point between A and B+ is then determined, producing DTA+.  Similarly, a 
dose distribution B- is created by multiplying the dose values in A by (1−n/100)=0.98 with 
the DTA at each point between A and B- determining DTA-.  At each point, the DTD to 
ensure a maximum of an n% local dose error will be the minimum of (DTA+, DTA-).  If one 
would like to know the DTD in terms of an absolute (# Gy) dose value, e.g. ΔD= 0.02DRx , 
then B+ =A+ΔD and B- =A−ΔD respectively in the computation of DTA+ and DTA-.     
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Figure 39: Basic flow diagram of the DTD algorithm for the case with ΔD being an absolute (# Gy) dose value.  
See text for full description of the method.   
In this study, the DTD is based upon an in-house developed C++ DTA algorithm.  The DTA 
algorithm progressively searches in shells of increasing radius (number of voxels) for the 
dose agreement point in matrix ܤേ which surrounds the point of interest from matrix A.  
Internally, the DTA algorithm tri-linear interpolates the dose to a 1×1×1 ݉݉ଷresolution in 
the search matrix to reduce errors inherent to the discrete voxel-based DTA algorithm 
used.  [Chapter 6] describes an algorithm that is both more accurate and more efficient 
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than the algorithm used in this chapter.  In fact, completion of this study in inspired the 
development of the [Chapter 5] algorithm. Similar DTA algorithms are described in 
references[59] [60] [61] [62].  
5.1.2  DTD example 
To demonstrate the utility of the DTD, an intensity modulated radiation therapy 
(IMRT) lung treatment plan is generated using ݈ܲ݅݊݊ܽܿ݁ଷ (Philips Medical Systems, 
Fitchburg, WI).  The plan uses an internal target volume (ITV), generated from the union of 
the clinical target volume (CTV’s) on all breathing phases of a 10 phase 4DCT (phase 0% 
to 90%) plus a 0.5 cm ITV-planning target volume (PTV) margin.  The treatment plan is 
generated on phase 0% (end of inhale). The minimum prescribed dose to the target is 66 
Gy using direct machine parameters optimization IMRT optimization with a 4×4×4 ݉݉ଷ 
dose grid resolution.  The DTD is computed for both 4×4×4 ݉݉ଷ  and 2×2×2 ݉݉ଷ dose 
grid resolutions based on the collapsed-cone dose algorithm dose values.  The figures 
show the 4×4×4 ݉݉ଷ results unless otherwise noted.   
Following planning, the DTD is determined for n=2% of the local dose computed on 
phase 0% (DTD2%), and for ΔD =1.32 (DTD1.32Gy) and 3.30 Gy (DTD3.30Gy), 
Corresponding with 2% and 5% of the prescription dose.  These values are chosen in 
accordance with suggested dose accuracy values listed in ICRU report #62.5 
To visualize and analyze DTD, the externally computed DTD values are loaded into  
Pinnacle as a beam in a separate trial and the monitor units  are adjusted so that  dose 
values can be interpreted as  distance values (in mm).  This enables viewing of isoDTD 
lines on the patient’s anatomy and creation of DTD volume histograms (DTDvh) using pre-
existing Pinnacle tools. 
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5.1.3  Comparison with dose gradient 
An approach similar to the DTD is to evaluate the gradient of the 3D dose 
distribution then divide the desired dose tolerance value by the dose gradient.  This method 
is called TDG, for tolerance divided by gradient.  The 3D-dose gradient is computed using 
the central difference method, yielding gradients in the x, y, and z directions.  TDG values 
are computed in two ways, one using the magnitude of the 3D dose gradient (TDG3D) and 
the other using the maximum of the dose gradient [∂D/∂x,∂D/∂y,∂D/∂z] in a given direction 
(TDGmax).  The TDG method is compared with the DTD method by comparing color wash 
distributions, DTDvhs with TDGvhs, and plotting point-by-point DTD values with respect to 
TDG values. 
5.2 Findings 
Figure 40 shows the isodose lines on phase 0% for the IMRT plan overlaid on a 
transverse slice of the patient’s anatomy.  This same transverse slice is used to show the 
DTD-values in the later figures.  Figure 41(a) shows the DTD2% overlaid on this transverse 
slice.  The maximum DTD2% value observed inside the CTV is 6 mm, with values of 1 to 4 
mm surrounding the CTV.  Within the entire image, DTD2% values as low as 0.1 mm are 
observed.   
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Figure 40: Isodose lines on phase 0% on a single transverse slice of the IMRT plan used in this study.  The 
minimum prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) 
and cord PRV (orange). 
 
Figure 41(b) shows color wash isoDTD’s for the DTD1.32Gy.  Outside the irradiated 
region, the plan can tolerate up to 10 mm DVF errors.  Inside the irradiated region, but 
outside the CTV in large dose gradient regions, DVF errors between 0.5-1 mm can be 
tolerated.  Inside the CTV, the plan can tolerate up to 4 mm DVF error. Similarly, Figure 
41(c) shows color wash isoDTD’s for the DTD3.3Gy.  The DTD3.30Gy differs from the 
DTD1.32Gy demonstrating the variation of DTD with the required dose accuracy.  Outside 
the irradiated region, the plan can tolerate up to 10 mm DVF errors.  Inside the irradiated 
region, but outside the CTV in large dose gradient regions, DVF errors between 1-8 mm 
can be tolerated.  Inside the CTV, the plan can tolerate up to 10 mm DVF errors. 
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(a) 
(b) 
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(c) 
Figure 41: Color wash of DTD values overlaid on a transverse slice of the patient anatomy.  Each color wash 
values represent the lower bound of the value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. (a) DTD2%; 
tolerance is 2% of the local dose value (b) DTD1.32Gy; tolerance is 1.32 Gy (2% of the prescription dose) and (c) 
DTD3.30Gy, tolerance is 3.30 Gy (5% of the prescription dose).  On this slice, in (a), outside the treatment region DTD 
values range from 0.1 to 1 mm, around the CTV values range from 1 to 4 mm, and inside the CTV DTDs up to 6 mm are 
observed.  In (b), inside the CTV volume the plan absorbs DVF 4 mm errors. In dose gradients around the CTV, 0.5 to 1 
mm DVF errors are permitted, and outside the treatment region DVF errors up to 10 mm are tolerated. In (c), inside the 
CTV, 10 mm DVF error is permitted.  In dose gradients around the CTV, 1 to 8 mm DVF errors are permitted, and outside 
the treatment region DVF errors up to 10 mm are tolerated. 
These results suggest that accurate DVF’s are not needed for the whole image for 
dose mapping purposes.  For the two DTD distributions calculated; both results show that 
in high dose gradient regions, spatial dose or DVF accuracy requirements are tight, 
whereas inside the CTV or outside the treatment region both requirements can be relaxed 
and the plan can absorb more errors.  While isoDTDs overlaid on the patient’s anatomy 
allow visual identification of areas which are tolerant or intolerant to DVF errors, to 
statistically interpret the spatial dose or DVF accuracy requirements, the DTD can be 
plotted as function of the volume of any structure.  Figure 42 shows an example DTDvhs 
for the CTV structure for the 3.30 Gy and 1.32 Gy dose difference DTD criteria.  From 
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these graphs, one can read out the DVF accuracy required as a function of the percentage 
volume of the structure.  While not as useful as 3D visualization of the DTD, these DTDvh’s 
enable simple statistical analysis of DTD properties.   
DTDs calculated based on the 2×2×2 ݉݉ଷ dose grid resolution (not shown) look 
similar to the 4×4×4 ݉݉ଷ results shown in [Figure 41].  DTD values should not vary 
significantly with dose grid resolution when the dose resolution is sufficient such that 
intermediate points can be tri-linear interpolated with errors small compared with the size of 
the DTD criteria.   For points within the patient contour, the average DTD values computed 
at the 4×4×4 ݉݉ଷ and 2×2×2 ݉݉ଷ resolutions differ by less than 0.05 mm, with a root-
mean-square difference of 0.7 mm.  Figure 42 shows that differences in the 3.3 Gy CTV 
DTDvh values are less than 0.5 mm for the different dose matrix resolutions.  The 
deviations are due to differences in dose values computed within the CTV for the different 
resolutions and due to limitations of the underlying DTA algorithm used.   
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Figure 42: CTV distance-to-difference volume histogram (DTDvh) for the DTD3.30Gy and DTD1.32Gy values.  
The DTD data indicates that ninety percent of the CTV can tolerate DVF errors up to 1.01 mm for ΔD= 1.32 Gy and 2.8 
mm for ΔD= 3.30 Gy.  30% of the CTV can tolerate DVF errors up to 2.1 mm for ΔD= 1.32 Gy and 6.6 mm for ΔD= 3.30 
Gy.  Also plotted is the histogram of the dose tolerance divided by gradient (TDG) values for a 3.30 Gy dose tolerance, 
which indicates that 90% of the CTV tolerated DVF errors up to 5 mm, and 30% of the volume can tolerate up to 12 mm 
errors.  DTD and TDG values shown are computed using a dose matrix resolution of 4×4×4࢓࢓૜, except for one 3.30 Gy 
DTD curve (noted as ࡰࢀࡰ૜.૜૙	ࡳ࢟2 mm dose resolution) computed with a 2×2×2 ࢓࢓૜,  dose matrix to show deviations 
caused by computing at a different dose resolution. 
The ܶܦܩଷ஽ image for 3.30 Gy dose difference tolerance (ܶܦܩଷ.ଷ଴	ீ௬ଷ஽ ) is shown in 
Figure 43.  Qualitatively, this image is similar to the DTD3.3Gy [Figure 41c] in dose 
gradient regions, but differs in regions inside the CTV and outside the radiation beams 
where ܶܦܩଷ.ଷ଴	ீ௬ଷ஽  indicates larger tolerances of DVF or spatial dose errors from the DTD 
method.  Figure 44 compares the point-by-point DTD3.30Gy values with the ܶܦܩଷ.ଷ଴	ீ௬ଷ஽  
values for dose points within the patient contour.  The banding in the DTD values is due to 
the 1×1×1 ݉݉ଷ resolution used within the DTA algorithm.  Generally, TDG values are 
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larger than DTD values for this case.  Poor correlation between DTD3.30Gy and ܶܦܩଷ.ଷ଴	ீ௬ଷ஽  
values is observed, especially for large values.  Points with large ܶܦܩଷ.ଷ଴	ீ௬ଷ஽  values yet 
small DTD3.30Gy values are detected.  The TDG is inversely proportional to the dose 
gradient.  Because ܶܦܩଷ஽ uses the magnitude of the gradient vector, which can have small 
components in one direction but large components in others, it can overestimate 
permissible spatial dose errors in low dose gradient region.  In high dose gradient region, 
the TDG can over- or underestimate spatial dose errors depending on  
the curvature of the dose distribution.   
 
Figure 43: Color wash of the	܂۲۵૜.૜૙۵ܡ૜۲ .  Small TDG values (1-4 mm) are observed inside the treated region excluding the 
CTV. 
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Figure 44: Scatter plot between the calculated DTD3.30Gy and the ܂۲۵૜.૜૙۵ܡ૜۲ .  Poor correlation between these 
quantities is observed, particularly at large values. 
TDGmax, which uses the maximum dose gradient, has similar poor correlation with 
the DTD (not shown).  Overall, the TDG method is limited in its ability to evaluate 
acceptable DVF errors.  
5.3  Discussion 
Current deformable image registration algorithm and associated DVFs are inherently 
inaccurate.  Several groups have been working on estimating the accuracy / uncertainty in 
deformable image registration algorithms [63] [64] [20] [16] [65] [14] [17]; however little 
work has been done on finding the required spatial accuracy of a DVF.  In this work, a 
simple algorithm is introduced to compute a distance to a dose difference tolerance that 
can be related to how accurate the DVF used in dose mapping has to be to ensure that the 
specified dose accuracy tolerance is not violated.   
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Current deformable image registration algorithms focus on creating an as-accurate-
as-possible registration for an entire image or restrict over a given region of interest.  The 
results of this work indicate that for dose mapping purposes, accurate registration is 
needed in high dose gradient regions, with less accuracy in uniform dose areas.  
Theoretically, a DIR algorithm could be written which emphasizes accuracy in dose 
gradient regions via methods such as voxel weighting, location of spline-interpolant knots, 
etc. 
For simplicity, the example presented in this work evaluated the DTD between 
phases of a 4D lung treatment plan.  Specifically, the DTD estimates the required DVF 
spatial accuracy needed to map dose delivered on the end of inhale breathing phase 
(phase 0%) to any of the other breathing phases.  The tolerance values are selected as if 
the full treatment delivery occurred on the phase 0% image set.  If dose delivery on multiple 
4D breathing phases is considered, the sum of the DVF induced dose mapping errors (from 
the different mappings) would need to be less than the tolerance value.  If the DTD dose 
error tolerance is equi-distributed among the breathing phases, the dose delivered and 
DTD threshold values change by the same fraction, resulting in the same DTD for the 
phase 0% to phase N% mappings as given above.  Alternatively, the DTD dose error 
tolerance could be unequally distributed among the different image sets, while still requiring 
that the total dose error induced is less than the threshold.  This complex analysis is left for 
further study.  
The example presented in this work utilized DTD tolerance values with respect to 
target dose values.  However, the DTD concept is general and DTDs can be computed to 
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arbitrary, even region of interest specific tolerances.  For example, for critical structures, an 
appropriate tolerance could be the maximum tolerated dose.   
The DTD tool provides qualitative utilities when interfaced with a treatment planning 
system; DTD can be visualized as iso-DTD lines/color washes that provide the planner with 
the ability to see geographical maps of tolerated and un-tolerated DVF errors before using 
a specified DVF with a given uncertainty for dose mapping.  DTD-volume histograms can 
provide volume-based statistical error analysis for targets, organs at risk, or arbitrary 
regions of interest in an image. 
The DTD tool is not limited to estimating the spatial accuracy of a DVF.  For a given 
dose difference tolerance (absolute or %) one can determine the distance error that can be 
tolerated before violating the specified dose accuracy.  For a CTV, the DTD can be used as 
a first estimate of how large a setup error can be before introducing a clinically significant 
dose error.  Similarly, knowledge of the maximum tolerated setup error can be used in plan 
evaluation, possibly affecting CTV-to-PTV or organ at risk -to-planning risk volume (PRV) 
planning margins. 
5.4 Summary 
This chapter introduces a new method which estimates how large a DVF error can 
be tolerated before introducing a potentially clinically significant error in the dose mapping 
processes.  The required DVF spatial accuracy will depend on the particular dose 
distribution.  For dose mapping, DVFs accuracy must be highest in dose gradient regions, 
while less accurate DVFs can be tolerated in uniform dose regions.  The DTD tool can be 
used as a first estimate of DVF required spatial accuracy and can be applied to other areas 
when the distance to a dose difference tolerance is required to be known. 
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6 A continuous 3D DTA algorithm    
In chapter 5, the distance to dose difference (DTD) tool was introduced to estimate 
the required spatial accuracy of a displacement vector field for 4D dose calculations.  As 
implemented, the DTD code is based on a pair of distance to agreement (DTA) 
calculations.  In chapter 5, an in-house DTA code that evaluates and interpolates on the 
discretely valued dose distribution was used. This method suffers from discretization and 
interpolation errors, causing discontinuities and inaccuracies in the determination of the 
required spatial accuracy of a DVF.   
In this chapter, a 3D gamma continuous code I wrote is described of which the DTA 
portion can be utilized for discretization and interpolation error-free DTD calculations.  
While the discrete DTA algorithm relies on an exhaustive point-by-point search in the 
calculated dose distribution and applies interpolation to find the point with the same 
measured dose point, the continuous 3D DTA algorithm finds the closest geometric 
distance between the two distributions by dividing the calculated (reference) dose 
distributions into simplexes.  The closest distance with the same dose point between any 
test dose point and these simplexes can be directly computed using matrix multiplication 
and inversion without the need of interpolating. 
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The flow work of the code, some QA test cases, and comparison results between 
discrete DTA (in house code) and continuous DTA (using the new code) are discussed in 
this chapter.    
6.1 Gamma Index 
The gamma index [60] has been used in medical physics practice in the comparison 
of two dose distributions (e.g. measured and calculated) as a measure of  agreement 
between the two dose distributions for QA purposes.  The gamma index is given by the 
following equation:   
ߛሺߩ଴ሬሬሬሬԦ) =݉݅݊ఘሬԦ(ට|ఘିఘబ	ሬሬሬሬሬሬሬሬሬሬሬሬሬԦ|ఋௗబమ ൅	
ሺ஽ሺఘሬԦሻି஽బሺఘሬԦబሻሻమ
ఋ஽బమ ) 
                                      (7) 
where ߜ݀଴ଶ is the distance criterion in mm and ߜܦ଴ଶ is the percentage dose difference 
criteria.  Agreement is defined as number of dose points in a required region of interest that 
have gamma ≤ 1 and typical passing criteria requires 90% of points with γ ≤ 1.  Typical 
distance/dose tolerance values are 3 mm / 3%. 
When the dose difference term in the above equation is zero (ሺܦሺߩԦሻ െ ܦ଴ሺߩԦ଴ሻሻଶሻ, gamma 
index becomes a DTA index.  
6.2 Continuous gamma 
Continuous gamma [59] relies on geometry principles to compute the gamma index.  
It is based on finding the closest distance from a test point to reference surface.  A 
reference surface can be divided into simplexes. A simplex with n=1 is a line, n=2 is a 
plane and n=3 is a tetrahedron.    
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6.2.1 2D continuous gamma 
 Figure 45 demonstrates finding geometric gamma for a two dimensional case, 
 
Figure 45: Demonstration of computing continuous gamma for a 2D case. (Figure is courtesy of Dr. James 
Gordon) 
With reference to Figure 45, assume that the gamma index is being computed for 
the top left grid location. The test image intensity (i.e., dose) at that point is denoted by 
Dtest. Surrounding grid squares may be divided into upper and lower triangles, as indicated 
by the shading of the  two regions. Consider the upper triangle associated with the grid 
offset (i,j). [In Figure 45 , i = 2 and j = –1]. Coordinates (α,β) denote an interior point within 
this triangle. The units of α and β are pixels.  Interior points have 0 < α, β < 1 with α + β < 1. 
Edge points have 0 ≤ α, β ≤ 1  with α = 0, β = 0 or α + β = 1.  
Denote the reference image dose at offset (i,j) by ܦ௜,௝, the reference image dose at 
offset (i+1, j) by Di+1, j, and the reference image dose at offset (i, j+1) by ܦ௜,௝ାଵ . Assuming 
that dose may be linearly interpolated within the triangle, the reference image dose D,  at 
point (α, β) may be expressed as: 
Dtest 
   α          Di,j
Di+1,j 
         D, 
Lower 
Triangle 
Upper 
Triangle 
i
j 
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ܦఈ,ఉ ൌ ሺ1 െ ߙ െ ߚሻ. ܦ௜,௝ ൅ ߙ. ܦ௜ାଵ,௝ ൅ ߚ. ܦ௜,௝ାଵ (8) 
And the reference distance ݌	to get to point (α, β) may be expressed as:  
݌ఈ,ఉ	ୀ	ሺଵିఈିఉሻ	ൈ	௣೔,ೕ	ା	ఈ	ൈ	௣೔శభ,ೕ	ା	ఉ	ൈ	௣೔.ೕశభ                                               (9) 
And the value of ᴦଶ at (α, β) is given by: 
ᴦ஽೟೐ೞ೟ଶ ൌ 	 ൬
100
ܦ௖௥௜௧൰
ଶ
ൈ ሺܦఈ,ఉ െ ܦ௧௘௦௧ܦ௧௘௦௧ ሻ
ଶ ൅ ሺݏ௣௜௫௘௟ݏ௖௥௜௧ ሻ
ଶ ൈ ሾሺ݅ ൅ ߙሻଶ ൅ ሺ݆ ൅ ߚሻଶሿ (10) 
where spixel is the pixel size, scrit is the distance criterion in pixel units, and Dcrit  is the dose 
criterion.  For the current application (computing DTA), spixel = 4 mm, scrit = 3mm, and Dcrit = 
0.001%. The later term makes Γ nearly equivalent to the DTA index, therefore, Γ and DTA 
are used interchangeably below. Using coordinate points instead of i and j offsets, such as 
in the triangle case we have 3 vertices:	 ଵܲ, ଶܲ and ଷܲ for the reference image and ଷܲ for the 
test image equation 10 can be rearranged into: 
ᴦଶ ൌ 		 ߢଶ 	ൈ ሾ	ሺ1 െ ߙ െ 	ߚሻ ൈ ݀ଵ ൅ ߙ ൈ ݀ଶ ൅ ߚ ൈ ݀ଷ െ ݀଴ሿଶ ൅
ߣଶሼሾ	ሺ1 െ 	ߙ െ 	ߚሻ ൈ ଵܲ௫ ൅ 	ߙ ൈ ଶܲ௫ ൅ ߚ ൈ ଷܲ௫ െ ௢ܲ௫ሿଶ ൅		 ሾ	ሺ1 െ 	ߙ െ 	ߚሻ ൈ
ଵܲ௬ ൅ 	ߙ ൈ ଶܲ௬ ൅ ߚ ൈ ଷܲ௬ െ ௢ܲ௬ሿଶ ൅	 ሾ	ሺ1 െ 	ߙ െ 	ߚሻ ൈ ଵܲ௭ ൅ 	ߙ ൈ ଶܲ௭ ൅ ߚ ൈ
ଷܲ௭ െ ௢ܲ௭ሿଶ  
(11) 
where ߢ ൌ 	 ଵ஽೎ೝ೔೟ൈௗబ and	ߣ ൌ 	
ௌ೛೔ೣ೐೗
௦೎ೝ೔೟ . 
Setting the derivatives of ᴦଶ	with respect to α and β equal to zero gives two linear 
equations which can be solved for α and β.  
߲ᴦଶ
߲ߙ ൌ ܽ1. ߙ ൅ ܾ1. ߚ ൅ ݀1 
 
                                                          (12) 
where ܽ1 and ܾ1 are the coefficents of α and β in equation 12 and  ݀1 is a constant. 
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߲ᴦଶ
߲ߚ ൌ ܽ2. ߙ ൅ ܾ2. ߚ ൅ ݀2 
(13)
where ܽ2 and ܾ2 are the coefficents of α and β in equation 13 and  ݀2 is a constant. 
 
 
ܽ1 ൌ 	2ߢଶ ൈ ሺܦଶ െ ܦଵሻଶ ൅ 2ߣଶ ൈ ሺ ଶܲ௫ െ ଵܲ௫ሻଶ ൅ 2ߣଶ ൈ ሺ ଶܲ௬ െ ଵܲ௬ሻଶ ൅ 2ߣଶ
ൈ ሺ ଶܲ௭ െ ଵܲ௭ሻଶ 
        
(14) 
 
Similarly, the coefficients of α and β and the constant in equation 13 are given by: 
 
ܽ2 ൌ 	2݇ଶ ൈ ሺܦଷ െ ܦଵሻ ൈ ሺܦଶ െ ܦଵሻ ൅ 2ߣଶ ൈ ሺ ଷܲ௫ െ ଵܲ௫ሻ ൈ ሺ ଶܲ௫ െ ଵܲ௫ሻ ൅ 2ߣଶ
ൈ ൫ ଷܲ௬ െ ଵܲ௬൯ ൈ ൫ ଶܲ௬ െ ଵܲ௬൯ ൅ 2ߣଶ ൈ ሺ ଷܲ௭ െ ଵܲ௭ሻ ൈ ሺ ଶܲ௭ െ ଵܲ௭ሻ 
        
(17) 
ܾ1 ൌ 	2݇ଶ ൈ ሺܦଶ െ ܦଵሻ ൈ ሺܦଷ െ ܦଵሻ ൅ 2ߣଶ ൈ ሺ ଶܲ௫ െ ଵܲ௫ሻ ൈ ሺ ଷܲ௫ െ ଵܲ௫ሻ ൅ 2ߣଶ
ൈ ൫ ଶܲ௬ െ ଵܲ௬൯ ൈ ൫ ଷܲ௬ െ ଵܲ௬൯ ൅ 2ߣଶ ൈ ሺ ଶܲ௭ െ ଵܲ௭ሻ ൈ ሺ ଷܲ௭ െ ଵܲ௭ሻ 
 
݀1 ൌ 	2݇ଶ ൈ ሺܦଶ െ ܦଵሻ ൈ ሺܦଵ െ ܦ଴ሻ ൅ 2ߣଶ ൈ ሺ ଶܲ௫ െ ଵܲ௫ሻ ൈ ሺ ଵܲ௫ െ ଴ܲ௫ሻ
൅ 2ߣଶ ൈ ൫ ଶܲ௬ െ ଵܲ௬൯ ൈ ൫ ଵܲ௬ െ ଴ܲ௬൯ ൅ 2ߣଶ ൈ ሺ ଶܲ௭ െ ଵܲ௭ሻ
ൈ ሺ ଵܲ௭ െ ଴ܲ௭ሻ 
 
 
         
 
(15) 
 
(16) 
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ܾ2 ൌ 	2ߢଶ ൈ ሺܦଷ െ ܦଵሻଶ ൅ 2ߣଶ ൈ ሺ ଷܲ௫ െ ଵܲ௫ሻଶ ൅ 2ߣଶ ൈ ሺ ଷܲ௬ െ ଵܲ௬ሻଶ ൅ 2ߣଶ
ൈ ሺ ଷܲ௭ െ ଵܲ௭ሻଶ	 
        
(18) 
 
݀2 ൌ 	2݇ଶ ൈ ሺܦଷ െ ܦଵሻ ൈ ሺܦଵ െ ܦ଴ሻ ൅ 2ߣଶ ൈ ሺ ଷܲ௫ െ ଵܲ௫ሻ ൈ ሺ ଵܲ௫ െ ଴ܲ௫ሻ ൅ 2ߣଶ
ൈ ൫ ଷܲ௬ െ ଵܲ௬൯ ൈ ൫ ଵܲ௬ െ ଴ܲ௬൯ ൅ 2ߣଶ ൈ ሺ ଷܲ௭ െ ଵܲ௭ሻ ൈ ሺ ଵܲ௭ െ ଴ܲ௭ሻ 
        
(19) 
 
Solving for α and β, 
ߙ ൌ 	ܾ1. ݀1 െ ܾ2. ݀1ܽ1. ܾ2 െ ܽ2. ܾ1                                                      (20) 
 
ߚ ൌ 	ܽ2. ݀1 െ ܽ1. ݀2ܽ1. ܾ2 െ ܽ2. ܾ1                                                      (21) 
 
If the resulting values correspond to an interior point (0 < α, β < 1 with α + β < 1), 
that point gives the candidate minimum value for ᴦ within the triangle. Minima on the 
triangle edges can be found similarly (edge points have 0 ≤ α,  β ≤ 1  with α = 0, β = 0 or α 
+ β = 1). The overall minimum for the triangle is the minimum of these points and the doses 
di, j, di+1, j and di, j+1. Iteration through all offsets (i, j) out to the specified search distance 
gives the global minimum value of ᴦ.  
ᴦ௧௥௜௔௡௚௟௘ ൌ min	ሺᴦ௜௡௧௘௥௜௢௥, ᴦ௘ௗ௚௘ଵ, 	ᴦ௘ௗ௚௘ଶ, ᴦ௘ௗ௚௘ଷሻ                                             (22) 
For a line case (n=1), equation 6 becomes: 
ᴦଶ ൌ 		 ߢଶ 	ൈ ሾ	ሺ1 െ ߙሻ ൈ ݀ଵ െ ݀଴ሿଶ ൅ ߣଶሼሾ ሺ1 െ ߙሻ ൈ ଵܲ௫ ൅ ߙ ൈ ଶܲ௫ െ (23) 
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௢ܲ௫ሿଶ ൅		 ሾ	ሺ1 െ 	ߙሻ ൈ ଵܲ௬ ൅ 	ߙ ൈ ଶܲ௬ െ ௢ܲ௬ሿଶ ൅ ሾ ሺ1 െ ߙሻ ൈ ଵܲ௭ ൅ ߙ ൈ ଶܲ௭ െ
௢ܲ௭ሿଶ  
After setting  ௗᴦ
మ
ௗఈ ൌ 0, separating the equation to get coefficient of α and solving for α, 
we get α = -c/a, where a is the coefficient of α in the linear equation and c is the constant 
part in the equation.  After that, the value of α is substituted in equation 23 to get the square 
of min gamma. 
6.2.2 3D continuous gamma 
The 3D derivation is similar to the 2D derivation, except n=3, the highest order 
simplex that must be considered is a tetrahedron, and the 3D reference dose distribution 
voxels are each divided into 5 tetrahedrons [Table 13]. T1 is the central tetrahedron with all 
sides equal; it has a volume 1/3 and vertices: (1,0,0), (0,1,0), (0,0,1), (1,1,1).  T2 has 
volume 1/6 and vertices: (0,0,0) [pyramid apex], (1,0,0), (0,1,0), (0,0,1).  T3 has volume 1/6 
and vertices: (1,0,1) [pyramid apex], (0,0,1), (1,1,1), (1,0,0).  T4 has volume 1/6 and 
vertices: (1,1,0) [pyramid apex], (0,1,1), (1,1,1), (1,0,0).  T5 has volume 1/6 and vertices: 
(0,1,1) [pyramid apex], (0,0,1), (1,1,1), (0,1,0).  As a check, in the above set of 20 vertices, 
the apexes should appear once.  All other vertices should appear 4 times: 4 + (20 -4)/4 = 8. 
Table 13: summary of tetrahedrons spatial coordinates and volume information. 
# of 
tetrahedron Vertices coordinate Volume 
1 (1,0,0)apex (0,1,0) (0,0,1) (1,1,1) 1/3 
2 (0,0,0)apex (1,0,0) (0,1,0) (0,0,1) 1/6 
3 (1,0,1)apex (0,0,1) (1,1,1) (1,0,0) 1/6 
4 (1,1,0)apex (0,1,1) (1,1,1) (1,0,0) 1/6 
5 (0,1,1)apex (0,0,1) (1,1,1) (0,1,0) 1/6 
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The equation for gamma continuous for the 3D case is written as: 
ᴦଶ ൌ 		 ߢଶ 	ൈ ሾ	ሺ1 െ 	ߙ െ ߚ െ ߱ሻ ൈ ݀ଵ ൅ ߙ ൈ ݀ଶ ൅ ߚ ൈ ݀ଷ ൅ ߱ ൈ ݀ସ െ ݀଴ሿଶ
൅ ߣଶሾ	ሺ1 െ 	ߙ െ 	ߚ െ ߱ሻ ൈ ଵܲ ൅ 	ߙ ൈ ଶܲ ൅ ߚ ൈ ଷܲ ൅ ߱ ൈ ସܲ
െ ௢ܲ௫ሿଶ 
 
(14) 
 
where ߱ is the z-coordinate in pixel units.  The solution in this case is more complicated 
than the 1D and 2D, after settingௗᴦ
మ
ௗఈ ൌ 0, 
ௗᴦమ
ௗఉ ൌ 0, 
ௗᴦమ
ௗఠ ൌ 0, we can solve for α, β and ω. 
The 3D gamma continuous computer algorithm is divided into 5 subroutines Figure 
46: (1) compute gamma for a point, (2) compute gamma for a line, (3) compute gamma for 
a triangle, (4) compute gamma for a tetrahedron, and (5) compute gamma continuous.  The 
compute gamma continuous subroutine is the primary subroutine.  It sets the coordinates in 
the 3D dose distribution points and calls the tetrahedron routine to compute gamma for the 
5 tetrahedrons.  The tetrahedron routine calls the triangle function 4 times for each 
tetrahedron, since there are 4 triangles in a tetrahedron.  The triangle function calls the line 
function 3 times for each triangle, since there are 3 lines to form a triangle and finally the 
line function calls the point function 2 times for each line, since 2 points form a line. 
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Figure 46: flow chart for the 3D gamma continuous code. 
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6.3 3D gamma QA test cases and results 
The tests were conducted on 3×3×3 known dose phantoms generated in Matlab.  
Some test cases were: Input same dose file, DTA is zero; Apply known displacement shifts 
to the evaluated phantom, DTA equals the shift; Check computing DTA on phantom edges; 
Swab images and compute DTA again; Transpose matrices, DTA should not change. 
6.3.1 Test case one 
The purpose of this test case is to test the code when both the test and the 
reference dose distributions are the same.  In this case, the DTA must equal zero Figure 
47.  
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(a) (b)     
(c) 
 
Figure 47: Test case one: Reference and test dose distributions are the same.  (a) is the reference dose with 
values of 3 (b) is the test dose and (c) is the DTA with expected values of zeros. 
6.3.2 Test case two 
In this test case, voxel (1,2,1) in the test image is shifted one voxel in the x-direction 
to generate the reference image.  Figure 48 shows reference image (a), test image (b), and 
computed DTA (c).  From the DTA figure, we can report that the DTA for voxel (1,2,1) is 
one pixel units as expected, since that voxel was shifted one voxel in one direction.  For 
voxel (2,2,1) in the test image, although, that voxel was also shifted  one voxel, the DTA 
reported was not one pixel since, the code finds the minimum gamma along the line 
between voxel (2,1,1) and voxel (3,2,1) where the minimum distance was computed as 
follows:  
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minP = 0.5*(ඥሺ3 െ 2ሻଶ ൅ ሺ2 െ 10ሻଶ ൅ ሺ1 െ 1ሻଶ  = 0.7 pixel, where α = 0.5. 
 
(a)   (b)      
 (c) 
 
Figure 48: 14 (a) Reference image showing all dose values are the same except one voxel in the middle has a 
value of 4.  (b) Test image with all voxels have value of 3 except the second voxel in the first row has a value of 4.  (c) is 
the computed DTA in pixel units. 
6.4 Comparison with discrete DTA code 
Test case two was repeated, but this time using the in-house discrete code used in 
Chapter 5 to compute DTD.  From Figure 49, (d) the discrete DTA code reported DTA 
values of one pixel for both voxel (1,2,1) and voxel (2,2,1), whereas continuous DTA 
reported a DTA value of 0.7 pixel for voxel (2,2,1), which shows that the discrete DTA failed 
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to detect any interior DTA values which will degrade the accuracy of the computed DTA 
values.   
(a)   (b)      
(c)  (d) 
 
Figure 49: (a) Reference dose showing all dose values are the same except one voxel in the middle has a value 
of 4.  (b) Test dose with all voxels have values of 3 except the second voxel in the first row has a value of 4.  (c) is the 
computed DTA in pixel units using DTA continuous code and (d) is the computed DTA in pixel units using discrete DTA 
code. 
6.5 Conclusion 
In comparison with discrete DTA on a phantom case, continuous DTA proved to be 
more accurate than discrete DTA. 3D DTA continuous was developed, proved to be more 
accurate than discrete DTA and is ready to use for DTD implementation on patient cases. 
 108 
7 Application of DTD on Patient cases 
 In this chapter, I implement both discrete and 3D continuous DTD on the 11 patient cases 
used in this thesis.  The first section of this chapter establishes the linear correlation 
between discrete and continuous DTD on all patients, providing further assurance that the 
algorithms compute the same quantity.  The second section presents DTD anatomical 
maps on patient cases for both discrete and continuous DTD, and the 3rd section draws a 
conclusion about the required spatial accuracy of a DVF used in dose mapping. 
7.1 Discrete and 3D continuous DTA linear correlation 
Figure 50, show scatter plots of the discrete DTD on the y-axis and the continuous 
DTD on the x-axis for patient P4P100 (Appendix VII contains the scatter plots for the rest of 
the patients Figure 95-Figure 104).  The plots show that there is a linear correlation 
between the two codes with an average linear correlation coefficient of 0.99.  To reduce 
voxel interpolation-related errors, all input dose distributions were computed at 
2×2×2	݉݉ଷdose grid size. 
The two red lines represent the maximum and minimum interpolation error which is 
equal to √2*voxel size.  Interpolation error occurs in adjacent voxels. In such cases, for a 
dose point in the test image, the corresponding dose point in the reference image is given 
by the continuous DTA as the dose point associated with the closest corner of the 
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reference voxel; however, for the discrete code, there is more than one potential location of 
the dose point candidate.  If the interpolation occurs on the opposite corner to the real dose 
point, the maximum bound of the interpolation error will be given by √2*voxel size. 
 
Figure 50: scatter plot of discrete versus continuous DTD in mm for patient P4P100. The two red lines represent 
the maximum and minimum interpolation error which is equal to √૛*voxel size. 
 
 
7.2 DTD application on patient cases 
In previous work [58], we introduced the DTD concept and implemented it on one 
patient case to estimate the required spatial accuracy of a DVF.  In this section, I 
implement both discrete and continuous DTD on 11 patient cases.   
Figure 51 displays the color-wash maps on transverse slices of the dose 
distributions (a), the discrete (left) and continuous (right) DTD (b), and the DTDs difference 
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(c) for patient P4P100 (Appendix VIII contains the DTD color-wash maps for the rest of the 
patients Figure 105-Figure 114). For most patients, results agree with what we have 
reported in our previous study on one patient case.  In dose gradients around the CTV, 1 to 
7 mm DVF errors are permitted, and outside the treatment region DVF errors up to 10 mm 
are tolerated.  Inside the CTV, up to 10 mm DVF errors are permitted depending on the 
uniformity of the dose distribution inside the CTV.   
As for P4P104 [Figure 108], inside the CTV, 1- 4 mm DVF error is permitted.  In 
dose gradients around the CTV, 0.5 to 6 mm DVF errors are permitted, and outside the 
treatment region, DVF errors up to 10 mm are tolerated.  The result for this patient is 
expected, since the dose distribution inside and around the CTV is not uniform.  This 
confirms what we reported in the previous DTD work, in dose gradient regions the DVF has 
to be more accurate than in uniform dose regions. 
Comparing both discrete and continuous DTD results, the 3D continuous code is 
faster than the discrete code. For a dose file of size 190x130x139 with dose grid size of 
2 ൈ 2 ൈ 2	݉݉ଷ the 3D continuous code takes about a day.  To lower errors due to dose 
interpolation the discrete code computations could take 2 to 3 days. The two color-wash 
maps looked similar and they were different in regions outside the patient surface and 
outside the radiation beams in low dose point values where the continuous code does not 
compute a DTD value (please note that for such regions a mask was applied on the 
discrete DTD files to make its values equivalent to the continuous code), inside the 
radiation beams the two codes gave identical results in sharp dose gradient regions and 
were different inside and around the CTV by an amount that ranges from 0.1 mm up to 
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√2*voxel size which corresponds to the maximum interpolation error that can occur using 
the discrete DTD code.   
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(a) 
(b) 
 
(c) 
Figure 51: (a) Isodose lines on a single transverse slice of the computed dose for P4P100.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue), and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values.  (c) Color 
wash of the difference between discrete and continuous DTDs. Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
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7.3 Conclusion 
The required spatial accuracy of a DVF was estimated for 11 lung cancer patients, 
using both discrete and continuous DTD codes.  Results agreed with what we reported in 
our previous DTD work.  For the one patient that showed big differences among all the 
dose mapping methods ( MD-Anderson), the DTD map shows DVF accuracy is needed 
near the GTV.  Thus, any small errors in the DVF reader could result in the large observed 
DME.  The required spatial accuracy of a DVF depends on the uniformity of the dose 
distribution, is patient specific, and is greater than 10 mm in regions outside radiation fields.  
Both discrete and continuous showed similar DTD maps; however, continuous DTD 
followed the shape of the dose distribution, eliminating discretization dose error and is 
faster than the discrete DTD computations. 
Finding the required spatial accuracy of a DVF has lots of benefits in the radiation 
therapy field.  For DIR algorithms, it serves as a QA benchmark for these algorithms and 
helps to better improve their accuracy and speed.  This thesis results show that a DVF 
does not have to be accurate in the whole image; thus, there is no need for the DIR 
algorithm to apply exhaustive computation to accurately generate DVF for the whole image. 
Including DTD results into 4D planning can further improve the accuracy of estimating the 
delivered dose to the patient.  Since our results show that DTD distribution is patient-
specific, visualizing DTD location maps on the patient anatomy before starting the dose 
mapping process can help in evaluating the location of acceptable and non-acceptable 
potential dose mapping error.  
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8 Thesis conclusion and future directions 
This thesis work addresses errors that might occur when intra-fraction 4D dose calculations 
are performed for lung cancer treatment site.  The work is divided into two specific aims.  In 
specific aim one, a study of DME by comparing dose mapping algorithms: Pinnacle, 
Dtransform, and Tri-linear (with voxel subdivisions n= 1, 2 3) with respect to EMCM was 
done under two different conditions.  The first part of specific aim one investigated the 
effect of choosing the planning target on DME, and the second part investigated the effect 
of changing the dose grid size on DME. 
In specific aim two, a new concept called DTD was introduced to estimate the 
required spatial accuracy of a DVF used in dose mapping.  A 3D continuous DTD algorithm 
was written and compared to discrete DTD code on phantom and patient cases. 
8.1 Thesis findings 
Specific aim one, part one study showed that, for breathing phase 50% on 11 
patients, tissue density gradients were highest around the edge of the tumor, compared to 
the CTV, and the PTV edge voxels. Thus, treatment plans generated with margin equal to 
zero on the tumor might yield the highest DME.  Under non-clinical conditions designed to 
maximize the DME clinical scenario and using a fine dose grid resolution of 2×2×2 ݉݉ଷ, 
treatment plans were generated directly on the tumor and 4D-dose distributions were 
generated for all patients using the above mentioned dose mapping algorithms. 
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For all patients, there was no clinical effect of DME on the MLD, lung V20, and 
Esophagus specified volume indices.  Statistically, lung V20 and MLD showed significance 
for the entire dose mapping algorithms. 
Two out of the 11 patients had D98 Pinnacle-DME of 4.4 (P4P103) and 1.2 (MD-
Anderson) Gy. For P4P103, dose profiles showed that the differences were located in the 
penumbra region.    
As for specific aim two, this thesis has the potential to improve DIR algorithms 
efficiency by introducing a DTD tool that estimates the required spatial accuracy of a DVF 
used for mapping the dose.  Our results showed that a DVF does not need to be accurate 
in the whole image.  DVF spatial accuracy for 11 patients is patient specific, and depends 
on uniformity of the dose distribution.   In sharp dose gradient regions, DVF spatial 
accuracy of ~ 1 mm is needed, while 8 to 10 mm DVF accuracy can be tolerated before 
introducing any dose mapping errors inside the CTV (unless the dose inside the CTV is not 
uniform as in the P4P104 case) and > 10 mm in the rest of the dose grid areas.  
The finding of this thesis work has the potential to increase the accuracy of 4D 
planning.  This is achievable by using the ETM with mass sub-voxel mapping for a dose 
mapping algorithm.  Although ETM with mass sub-voxel mapping results were similar to 
Pinnacle and Tri-linear with sub-voxel dose mapping algorithms, ETM accurately transports 
the energy events point by point on each of the breathing phases and deposits the energy 
in the reference breathing phase.  The mass sub-voxel mapping implementation in ETM 
method increases the accuracy of ETM by mapping the mass of the breathing phases at 
almost a CT image resolution.  ETM provides spatial energy distribution information, 
whereas only information about the average mapped energy is known for Dtransform.  
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Along with enforcing a 1 mm DVF spatial accuracy in dose gradient regions, an accurate 
estimation of the dose delivered to patient is achieved within 5% of the prescribed dose 
(uncertainty in MC calculations is < 2% and DTD criteria is set to 5% of the prescribed 
dose). 
These thesis results also highlight the importance of choosing the planning target 
when designing a 4D plan.  Results 0 showed that choosing the GTV as the planning target 
has the potential to cause high DME.  Although having the GTV as the planning target is 
not clinically approved, current IGRT and SBRT plans aim to directly track the tumor dose 
and reduce margins around the tumor.  For current clinical IMRT plans that utilize the use 
of margin around the tumor to reduce setup error, the results for two patients showed that 
using the PTV margin around the ITV (including tumor motion), will help in reducing the 
DME.  The DTD results emphasize the importance of the uniformity of the dose around the 
target, since large DTDs, and thus tolerated spatial dose errors, are observed in regions of 
homogeneous doses around the GTV.     
The final fruit of this thesis work is to provide more accurate and efficient DTA 
algorithm than a current in-house DTA algorithm, for that reason, based on an existing 2D 
DTA code, I wrote a 3D DTA algorithm that is free from discretization and interpolation error.  
The continuous 3D DTA is a multi-purpose algorithm that can compute a 3D gamma index 
and a 3D DTA index, which is the basic index to compute the DTD.  The 3D continuous 
DTD algorithm is written, on dose phantom cases, is more accurate than the discrete DTD, 
and on patient cases, continuous DTD computations follow the shape of the dose 
distribution better than the discrete DTD code. 
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In conclusion, DME is patient specific and depends highly on the dose conformity 
level around the tumor.  D98 RMS DME between ETM and DIM (Tri-linear) was reduced 
when a 2×2×2 ݉݉ଷ planning dose grid size was used.  Thus for patients with small tumor 
motion and deformation, at 2×2×2 ݉݉ଷ	planning dose grid size it does not matter which 
dose mapping algorithm to use for mapping the dose. Cases where there is large organ 
deformation we recommend using the EMCM algorithm even at 2×2×2 ݉݉ଷ.  Spatial 
accuracy of the DVF is patient specific and is dependent on the uniformity of the dose 
distribution. 
8.2 Future directions 
The dose mapping study was done for intra-fraction 4D dose calculation for lung. It 
will be interesting to repeat the same study for inter-fraction 4D dose calculation for lung 
and for different treatment sites example head and neck, and abdominal cancers. Also, it is 
interesting to include different treatment modalities. 
As for the DTD study, DTD calculation on more patients, different cancer sites and 
different modalities are interesting continuing studies.   
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Figure 52: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P101.  The yellow vectors represent the DVFs (0->N%). 
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Figure 53: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P102.  The yellow vectors represent the DVFs (0->N%). 
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Figure 54: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P103.  The yellow vectors represent the DVFs (0->N%). 
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Figure 55: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P104.  The yellow vectors represent the DVFs (0->N%). 
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Figure 56: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P105.  The yellow vectors represent the DVFs (0->N%). 
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Figure 57: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P106.  The yellow vectors represent the DVFs (0->N%). 
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Figure 58: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P107.  The yellow vectors represent the DVFs (0->N%). 
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Figure 59: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P110.  The yellow vectors represent the DVFs (0->N%). 
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Figure 60: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient P4P114.  The yellow vectors represent the DVFs (0->N%). 
 
 148 
 149 
Figure 61: transverse, sagittal, and coronal views of the planning phase (0%) showing the generated GTV0 
(PIDVF N%->0) on phase N% mapped back to phase 0% using the Pinnacle DVFs (0->N%)(green) and the manual GTV 
on phase 0% for patient MD-Anderson.  The yellow vectors represent the DVFs (0->N%). 
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Figure 62: Patient P100 complementary cumulative distribution sum of the frequency of the PTV, CTV, and 
tumor edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV ,and tumor 
curves. 
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Figure 63: Patient P101 complementary cumulative distribution sum of the frequency of the PTV, CTV, and 
tumor edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV, and tumor 
curves. 
 
Figure 64: Patient P102 complementary cumulative distribution sum of the frequency of the PTV, CTV and tumor 
edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV and tumor curves. 
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Figure 65: Patient P103 complementary cumulative distribution sum of the frequency of the PTV, CTV and tumor 
edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV and tumor curves. 
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Figure 66: Patient P104 complementary cumulative distribution sum of the frequency of the PTV, CTV and tumor 
edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV and tumor curves. 
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Figure 67: Patient P105 complementary cumulative distribution sum of the frequency of the PTV, CTV and tumor 
edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV and tumor curves. 
 155 
 
Figure 68: Patient P106 complementary cumulative distribution sum of the frequency of the PTV, CTV and tumor 
edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV and tumor curves. 
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Figure 69: Patient P107 complementary cumulative distribution sum of the frequency of the PTV, CTV and tumor 
edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV and tumor curves. 
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Figure 70: Patient P110 complementary cumulative distribution sum of the frequency of the PTV, CTV and tumor 
edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV and tumor curves. 
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Figure 71: Patient P114 complementary cumulative distribution sum of the frequency of the PTV, CTV and tumor 
edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV and tumor curves. 
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Figure 72: Patient MD-Anderson complementary cumulative distribution sum of the frequency of the PTV, CTV 
and tumor edge voxels on the y-axis versus phase 50 % image gradient on the edge voxels of the PTV, CTV and tumor 
curves. 
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Table 14: 4D-DVHs of the accumulated dose on the reference phase for each patient on the left.  On the right is the 
difference in DVH indices among dose mapping methods with respect to EMCM: tumor D98, D50, mean lung dose, dose 
to 10 0r 1% of the cord in cGy and  percentage difference in volume indices for lung, Esophagus and normal tissue.   
 
 
 
P4P100  Pin  N1  N2  N3     
 
Dtra 
 
D98 cGy ‐12 ‐4 ‐3  ‐3  ‐5.5
D50 cGy 0.1 4 4  4  ‐5
Lung V20
%  0.35  0.4  0.35  0.35  0.35 
MLD cGy 19 18 18  18  19
Esophagu
s V55 %  ‐0.2  
‐0.1  ‐0.2  ‐0.2  ‐0.2 
Heart V40
%  0.1  0.1  0.1  0.1  0.1 
Cord D10 
cGy  68  ‐29  ‐30  ‐32  ‐30 
Normal 
tissue 
V20 % 
1  1  1  1  0.98 
 
P4P101  Pin  N1  N2  N3 
 
Dtran 
 
D98 cGy ‐11   1 5  5    13.2
D50 cGy 2 2 2  2  1.77
Lung V20 % 0.7 0.7 0.7  0.7  0.74
MLD cGy 36 35 35  35  36
Esophagus 
V55 %  ‐0.1  ‐0.1  ‐0.1  ‐0.1  ‐0.1 
Heart
V10 %  2  2  2  2  2 
Cord D1 
cGy  ‐19  ‐9  ‐9  ‐13  ‐8.3 
Normal 
tissue 
V10 % 
3  3  3  3  2.6 
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P4P102  Pin  N1  N2  N3 
 
Dtra 
 
D98 cGy 44 37 37  37   36.6
D50 cGy 3 6 6  5  5.7
Lung V20
%  0.02  0  0  0  0 
MLD cGy 42 43 43  43  43
Esophagus 
V35 %  0.2  ‐0.1  ‐0.01  ‐0.01  ‐0.06 
Heart
V10 %  3  3  3  3  2.76 
Cord D1 
cGy  37  55  56  56  54 
Normal 
tissue 
V20 % 
2  1.5  1.5  1.5  1.5 
 
 
P4P103  Pin  N1  N2  N3 
 
Dtra 
 
D98 cGy ‐414 ‐229 ‐229  ‐229  ‐140
D50 cGy 3 6 5.6  5.5  ‐4.3
Lung V20
%  0.8  0.9  0.9  0.9  0.56 
MLD cGy 31 31 31  31  20
Esophagus 
V20 %  ‐0.2  ‐0.02  ‐0.02  ‐0.02  ‐0.06 
Heart
V10 %  0.8  0.7  0.7  0.7  0.4 
Cord D1 
cGy  ‐14  ‐5.3  ‐7  ‐8  ‐6.5 
Normal 
tissue 
V20 % 
2  2.5  2.5  2.5  1.6 
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P4P104  Pin  N1  N2  N3 
 
Dtran 
 
 
D98 cGy 35 15 19  20   14
D50 cGy 3 0.1 2  2  0.75
Lung V20 % 0.4 0.4 0.4  0.2  0.33
MLD cGy 50 52 52  52  46
Esophagus 
V55 %  ‐0.2  ‐0.02  0  0  0 
Heart
V40 %  0.2  0.1  0.1  0.1  0.07 
Cord D1 
cGy  1.9  5  5  5  4.74 
Normal 
tissue 
V20 % 
0.1  0.3  0.2  0.2  2 
 
 
 
P4P105  Pin  N1  N2  N3  Dtra  
D98 cGy ‐54 ‐15 ‐22  ‐24  ‐10.36
D50 cGy ‐17 ‐17 ‐12  ‐13  ‐11.65
Lung V20 % 0.1 0.2 0.2  0.2  0.2
MLD cGy 5.7 7.6 7.6  7.6  8.3
Esophagus 
V20 %  0.04  ‐0.08  ‐0.08  ‐0.07  0 
Heart
V40  %  0  0.03  0.03  0.03  0 
Cord D1 
cGy  ‐11  ‐9  ‐9  ‐9  ‐6 
Normal 
tissue 
V20 % 
0.3  0.5  0.5  0.5  0.5 
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P4P106  Pin  N1  N2  N3  Dtra  
D98 cGy 11 11 12  12  9.76
D50 cGy ‐3.5 ‐8 ‐8  ‐8  ‐8.6
Lung V20 % 0.1 0.2 0.25  0.25  0.24
MLD cGy 13 17 17  17  16
Esophagus 
V55 %  ‐0.3  ‐0.2  ‐0.2  ‐0.2  ‐0.16 
Heart
V10 %  0.2  0.3  0.3  0.3  0.3 
Cord D1 
cGy  ‐26  ‐5  ‐10  ‐10  ‐6 
Normal 
tissueV20  0.5  0.5  0.5  0.5  0.45 
 
 
P4P107  Pin  N1  N2  N3  Dtra  
D98 cGy ‐23 33 ‐37  ‐39  ‐17.5
D50 cGy ‐8 ‐7 ‐8  ‐15  ‐6.82
Lung V20 %  ‐0.03  0.15  0.14  0.1  0.14 
MLD cGy 3 7 7  7  7
Esophagus 
V25 %  ‐0.2  0.1  0.1  0.1  0.1 
Heart
V40 %  NA  NA  NA  NA  NA 
Cord D1 
cGy  ‐4  0.6  0.5  0.2  0.2 
Normal 
tissue 
V20 % 
‐
0.06  0.3  0.3  0.3  0.3 
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P4P110  Pin  N1  N2  N3  Dtra  
D98 cGy ‐36 ‐5 ‐8  ‐9  0.3
D50 cGy ‐11 ‐7 ‐7.5  ‐7.6  ‐7.23
Lung V20 % 0.03 0.1 0.1  0.08  0.06
MLD cGy 12.2 5.3 5.3  5.3  4.1
Esophagus 
V20 %  ‐0.1  ‐0.05  ‐0.06  ‐0.06  ‐0.04 
Heart
V40 % 
 
‐
0.02  0  0  0  0 
Cord D1 
cGy  ‐22  ‐8  ‐10  ‐10  ‐9.2 
Normal 
tissueV20 
% 
0.3  0.3  0.3  0.3  0.21 
 
 
P4P14  Pin  N1  N2  N3  Dtra  
D98 cGy ‐61 ‐37 ‐39  ‐40  ‐27
D50 cGy  ‐11.4  ‐7  ‐7.5  ‐7.6  ‐7 
Lung V20 % 0.1 0.5 0.5  0.5  0.3
MLD cGy 5 21 21  21  11
Esophagus 
V55 %  0.7  ‐0.4  ‐0.4  ‐0.4  ‐0.4 
Heart
V40 %  0.6  0.1  0.1  0.1  0.07 
Cord D10 
cGy  37  17.5  19  19  3.6 
Normal 
tissueV20 
% 
0.5  1  1  1  0.6 
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MD‐
Anderson  Pin  N1  N2  N3 
Dtra 
 
D98 cGy 118 ‐42 ‐34  ‐33  ‐71
D50 cGy 114 ‐29 ‐24  ‐20  ‐30
Lung V20 % 0.3 0 0  0  0
MLD cGy 17 2 2  2  2.7
Esophagus 
V10 %  3  ‐0.03  ‐0.06  ‐0.06  ‐0.2 
Heart
V10 %  0.7  0  ‐0.03  ‐0.03  ‐0.12 
Cord D1 
cGy  ‐43  3.5  6  6  2.4 
Normal 
tissueV20 
% 
0.3  0.04  0.01  0.01  ‐0.15 
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Figure 73: P4P100 coronal slices showing the location of maximum absolute DME for Dtransform on the left, Tri-
linear with n =3 in the middle, and Pinnacle on the right.  Shown in red color-wash is the tumor. The maximum absolute 
DME point was located outside the patient. 
Figure 74: P4P101 coronal slices showing the location of maximum absolute   DME for Pinnacle on the left, Tri-
linear with n =3 in the middle, and Dtransform on the right. Shown in red color-wash is the tumor.  
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Figure 75: P4P102 coronal slices showing the location of maximum absolute DME for Pinnacle on the left, Tri-
linear with n =3 in the middle, and Dtransform on the right. Shown in red color wash is the tumor. 
   
 
Figure 76: P4P103 coronal slices showing the location of maximum absolute DME for Pinnacle on the left, Tri-
linear with n =3 in the middle and Dtransform on the right. Shown in red color wash is the tumor. 
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Figure 77: P4P104 coronal slices showing the location of maximum absolute DME for Pinnacle on the left, Tri-
linear with n =3 in the middle and Dtransform on the right. Shown in red color wash is the tumor. 
Figure 78: P4P105 coronal slices showing the location of maximum absolute DME for Pinnacle on the left, Tri-
linear with n =3 in the middle and Dtransform on the right. Shown in red color wash is the tumor.  The maximum absolute 
DME point was located outside the patient surface. 
 
Figure 79: P4P106 coronal slices showing the location of maximum absolute DME for Pinnacle on the left, Tri-
linear with n =3 in the middle and Dtransform on the right. Shown in red color wash is the tumor.  The maximum absolute 
DME point was located on the patient surface for Pinnacle and tri-linear, and outside the radiation field for Dtransform. 
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Figure 80: P4P107 coronal slices showing the location of maximum absolute DME for Pinnacle on the left, Tri-
linear with n =3 in the middle and Dtransform (sagital) on the right. Shown in red color wash is the tumor.  The maximum 
absolute DME point was located inside the radiation field but away from the tumor.  
Figure 81: P4P110 coronal slices showing the location of maximum absolute DME for Pinnacle on the left, Tri-
linear with n =3 in the middle and Dtransform on the right. Shown in red color wash is the tumor.  The maximum absolute 
DME point was located outside the patient surface. 
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Figure 82: P4P114 coronal slices showing the location of maximum absolute DME for Pinnacle on the left, Tri-
linear with n =3 in the middle and Dtransform on the right. Shown in red color wash is the tumor.  The maximum absolute 
DME point was located outside the patient surface.  
 
Figure 83: MD Anderson coronal slices showing the location of maximum absolute DME for Pinnacle on the left, 
Tri-linear with n =3 in the middle and Dtransform on the right. Shown in red color wash is the tumor.  The maximum DME 
point was located outside the patient surface. 
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Figure 84: P4P100 coronal slices showing the location of maximum DME for Dtransform on the left, Tri-linear 
with n =3 in the middle, and Pinnacle on the right.  Shown in blue color-wash is the tumor.  
Figure 85: P4P101 coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear with n 
=3 in the middle, and Dtransform on the right. Shown in red color-wash is the tumor.  
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Figure 86.  P4P102 coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear with 
n =3 in the middle, and Dtransform on the right. Shown in red color wash is the tumor. 
   
Figure 87: P4P103 coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear with n 
=3 in the middle and Dtransform on the right. Shown in red color wash is the tumor. 
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Figure 88: P4P104 coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear with n 
=3 in the middle and Dtransform on the right. Shown in red color wash is the tumor. 
Figure 89: P4P105 coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear with n 
=3 in the middle and Dtransform on the right. Shown in red color wash is the tumor. 
Figure 90: P4P106 coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear with n 
=3 in the middle and Dtransform on the right. Shown in red color wash is the tumor. 
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Figure 91: P4P107 coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear with n 
=3 in the middle and Dtransform (sagital) on the right. Shown in red color wash is the tumor. 
Figure 92: P4P110 coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear with n 
=3 in the middle and Dtransform on the right. Shown in red color wash is the tumor. 
 
 175 
Figure 93: P4P114 coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear with n 
=3 in the middle and Dtransform on the right. Shown in red color wash is the tumor.  
 
Figure 94: MD Anderson coronal slices showing the location of maximum DME for Pinnacle on the left, Tri-linear 
with n =3 in the middle and Dtransform on the right. Shown in red color wash is the tumor. 
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Table 15: 4D-DVHs of the accumulated dose on the reference phase for each patient using ૝ ൈ ૝ ൈ ૝	࢓࢓૜  and 
૛ ൈ ૛ ൈ ૛	࢓࢓૜ on the left.  On the right are tables for each patient with data that corresponds to the absolute difference in 
OAR 4D-DVH volume indices with respect to EMCM 2 ×2 ×2  ࢓࢓૜ for both dose grid sizes for EMCM, N1, N3, and 
Pinnacle dose mapping algorithms.  
   
  4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ହܸହீ௬
0.1  0.1  0.1  0.1  0.1  0.1  0.1 
Hear
t(%) 
ସܸ଴ீ௬
0.6  0.3  0.3  0.3  0.4  0.4  0.3 
Lung
(%) 
ଶܸ଴ீ௬
0.1  0.2  0.1  0.1  0.7  0.7  0.7 
Cord
(cGy) 
ܦଵ%  
7  9  6  12  8.6  12.6  18.7 
N.T(
%) 
ଵܸ଴ீ௬
1.8  5  5  5  3  3  3 
 
 
  4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ଷܸହீ௬
2.4  1  1  1.5  0.1  0.01  0.22 
Hear
t(%) 
ଵܸ଴ீ௬
2  0.8  0.8  0.8  2.8  2.8  2.9 
Lung
(%) 
ଶܸ଴ீ௬
0.35  0.4  0.4  0.5  0.005  0 
0.0
2 
Cord
(cGy) 
ܦଵ%  
191  226  223  216  55  56  37 
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N.T(
%) 
ଶܸ଴ீ௬
3.5  2  2  2  1.5  1.5  1.6 
 
 
4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ଶܸ଴ீ௬
1  1  1  1  0.02  0.02  0.2 
Hear
t(%) 
ଵܸ଴ீ௬
0.98  0.3  0.25  0.2  0.7  0.7  0.8 
Lung
(%) 
ଶܸ଴ீ௬
0.04  0.9  0.9  0.8  0.9  0.9  0.8 
Cord
(cGy) 
ܦଵ%  
8  13  9  24  5  8  14 
N.T(
%) 
ଶܸ଴ீ௬
0.07  2  2  2  2  2  2 
4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ହܸହீ௬
0.3  0.3  0.3  0.5  0.02  0.007  0.2 
Hear
t(%) 
ସܸ଴ீ௬
0.7  0.7  0.7  0.6  0.1  0.1  0.2 
Lung
(%) 
ଶܸ଴ீ௬
0.4  0.85  0.9  0.8  0.4  0.4  0.35 
Cord
(cGy) 
ܦଵ%  
14  39  60  40  5  5  2 
N.T(
%) 
଺ܸ଺ீ௬
0.75  0.8  1  0.9  0.3  0.2  0.1 
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4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ଶܸ଴ீ௬
0.5  0.6  0.7  0.8  0.08  0.07  0.04 
Hear
t(%) 
ସܸ଴ீ௬
1  1  1  1  0.03  0.03  0.006 
Lung
(%) 
ଶܸ଴ீ௬
0.1  0.01  0.03  0.1  0.2  0.2  0.08 
Cord
(cGy) 
ܦଵ%  
127  108  88  101  9  9  11 
N.T(
%) 
ଶܸ଴ீ௬
0.04  0.5  0.5  0.3  0.5  0.5  0.3 
 
 
4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ହܸହீ௬
0.35  0.7  1  1  0.2  0.2  0.3 
Hear
t(%) 
ଵܸ଴ீ௬
0.6  0.2  0.2  0.2  0.3  0.3  0.2 
Lung
(%) 
ଶܸ଴ீ௬
0.3  0.1  0.1  0.2  0.2  0.2  0.1 
Cord
(cGy) 
ܦଵ%  
6  23  40  39  5  10  26 
N.T(
%) 
ଶܸ଴ீ௬
0.02  0.4  0.5  0.5  0.5  0.5  0.5 
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4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ଶܸହீ௬
3  3  3  2  0.1  0.1  0.2 
Hear
t(%) 
ସܸ଴ீ௬
N/A  N/A  N/A  N/A  N/A  N/A  N/A 
Lung
(%) 
ଶܸ଴ீ௬
0.3  0.2  0.3  0.4  0.15  0.1  0.03 
Cord
(cGy) 
ܦଵ%  
220  205  218  217  0.6  0.2  4 
N.T(
%) 
ଶܸ଴ீ௬
0.04  0.2  0.1  0.1  0.3  0.3  0.06 
 
 
4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ଶܸ଴ீ௬
0.3  0.3  0.3  0.2  0.1  0.1  0.2 
Hear
t(%) 
ସܸ଴ீ௬
0.4  0.4  0.4  0.4  0.006 
0.00
3 
0.0
2 
Lung
(%) 
ଶܸ଴ீ௬
0.2  0.1  0.2  0.2  0.1  0.08  0.03 
Cord
(cGy) 
ܦଵ%  
41  56  71  67  8  10  22 
N.T(
%) 
ଶܸ଴ீ௬
0.1  0.3  0.3  0.2  0.3  0.3  0.3 
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4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ହܸହீ௬
1.6  1.8  1.8  1.5  0.4  0.4  0.7 
Hear
t(%) 
ସܸ଴ீ௬
0.88  0.85  0.85  0.93  0.1  0.1  0.6 
Lung
(%) 
ଶܸ଴ீ௬
0.3  0.1  0.1  0.2  0.5  0.5  0.1 
Cord
(cGy) 
ܦଵ%  
39  32  24  32  0.3  2  88 
N.T(
%) 
ଶܸ଴ீ௬
0.35  0.1  0.1  0.8  0.1  0.1  0.3 
4 ൈ 4 ൈ 4 ݉݉ଷ 
 
					2 ൈ 2 ൈ 2	݉݉ଷ 
 
  EMCM N1  N3  Pin  N1  N3  Pin 
Eso(
%)
ଵܸ଴ீ௬
0.08  1  1  1  0.03  0.06  3 
Hear
t(%) 
ଵܸ଴ீ௬
0.05  0.5  0.6  0.4  0.003  0.03  0.7 
Lung
(%) 
ଶܸ଴ீ௬
0.08  0.1  0.1  0.15  0.004  0  0.3 
Cord
(cGy) 
ܦଵ%  
97  96  100  85  3.5  6  43.5 
N.T(
%) 
ଶܸ଴ீ௬
0.35  0.7  0.9  1  0.04  0.01  0.3 
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Table 16: 4D-DVHs of the accumulated dose on the reference phase for each patient for the 4 mm dose grid size on the 
left.  On the right is the difference in DVH indices among dose mapping methods with respect to EMCM: tumor D98, D50, 
mean lung dose, dose to 10 0r 1% of the cord in cGy and  percentage difference in volume indices for lung, Esophagus 
and normal tissue.   
P4P100  Pin  N1  N2  N3 
 
Dtran 
 
D98 cGy ‐40 ‐43 ‐61 ‐63  ‐21
D50 cGy ‐11 ‐10 ‐13 ‐13  ‐8
Lung V20 % 0.3 0.3 0.3 0.3  0.3
MLD cGy 20 19.5 19.5  19.5  20
Esophagus 
V55 %  ‐0.16  ‐0.18  ‐0.34  ‐0.34  ‐0.2 
Heart
V40 %  0.1  0.1  0.1  0.1  0.1 
Cord D10
cGy  ‐77  ‐58  ‐53  ‐53  ‐58 
Normal 
tissue 
V20 % 
0.95  0.9  0.9  0.9  0.9 
 
P4P101  Pin  N1  N2  N3 
 
Dtran 
 
D98 cGy 101.4 114.9 87.7  82  130
D50 cGy ‐6.77 ‐2.89 ‐7.67  ‐8.63  ‐3.18
Lung V20 % 0.7 0.7 0.7 0.7  0.7
MLD cGy 0.2 0.1 0 0  0
Esophagus 
V55 %  ‐0.03  ‐0.03  ‐0.03  ‐0.03  ‐0.03 
Heart
V10 %  1.8  1.65  1.7  1.7  1.7 
Cord D1 cGy 5.7 1.88 0.36  ‐0.53  2
Normal 
tissue 
V10 % 
3  2.6  2.7  2.75  2.6 
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P4P102  Pin  N1  N2  N3 
 
Dtra 
 
D98 cGy ‐24 ‐28 ‐33  ‐34  ‐21
D50 cGy 5 6 5 5  5
Lung V20 % 0.13 0.02 0.03  0.03  0.003
MLD cGy 44 41 41  41  43
Esophagus 
V35 %  0.87  ‐1  ‐1  ‐1  ‐1 
Heart
V10 %  3  3  3  3  2.4 
Cord D1 cGy  22  36  32                   32  35 
Normal 
tissue 
V20 % 
1.3  1.2  1.3  1.3  1.6 
 
 
P4P103  Pin  N1  N2  N3 
 
Dtra 
 
D98 cGy ‐388 ‐208.5 ‐244.6  ‐243.6  ‐175
D50 cGy ‐15.4 ‐13.9 ‐17.8 ‐18.5  ‐11.8
Lung V20 % 0.9 0.97 0.95 0.95  0.8
MLD cGy 33 33 33 33  29.7
Esophagus 
V20 %  ‐0.2  ‐0.05  ‐0.06  ‐0.08  ‐0.09 
Heart
V10 %  0.8  0.7  0.7  0.7  0.7 
Cord D1 cGy ‐16.2 ‐5 ‐1.2 ‐1.2  ‐3.6
Normal 
tissue 
V20 % 
2.4  2.5  2.5  2.5  2.1 
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P4P104  Pin  N1  N2  N3  Dtra  
D98 cGy 49 32 45 49  27
D50 cGy 6 0.4 6 6  ‐2
Lung V20 % 0.4 0.4 0.5 0.5  0.5
MLD cGy 48 51 51 51  50
Esophagus 
V55 %  0.15  ‐0.1  ‐0.1  ‐0.1  ‐0.02 
Heart
V10 %  0.1  ‐0.01  ‐0.03  ‐0.04  ‐0.02 
Cord D1 cGy ‐26 ‐25 ‐38 ‐46  ‐25
Normal 
tissueV20  ‐0.1  ‐0.01  ‐0.2  ‐0.3  ‐0.03 
 
 
 
P4P105  Pin  N1  N2  N3  Dtra  
D98 cGy ‐68 ‐38.5 ‐69 ‐71  ‐17.4
D50 cGy ‐22 ‐20 ‐26.2  ‐26.8  ‐16.5
Lung V20 % 0.06 0.1 0.1 0.1  0.13
MLD cGy 5.5 6.9 6.8 6.8  8
Esophagus 
V20 %  0.3  ‐0.14  ‐0.19  ‐0.19  0.15 
Heart
V40  %  ‐0.02  0.01  0.02  0.02  0 
Cord D1 cGy ‐26 ‐19 ‐‐37.6  ‐39  ‐19.7
Normal 
tissue 
V20 % 
0.3  0.5  0.5  0.5  0.5 
 
 
 
P4P106  Pin  N1  N2  N3  Dtra  
D98 cGy ‐25 ‐12 ‐18 ‐19.7  ‐10.2
D50 cGy ‐9 ‐9 ‐9.7 ‐9.7  ‐8.5
Lung V20 % 0.1 0.2 0.2 0.2  0.2
MLD cGy 14 15 15 15  15
Esophagus 
V55 %  ‐0.7  ‐0.7  ‐0.6  ‐0.6  ‐0.39 
Heart
V10 %  0.4  0.4  0.4  0.4  0.4 
Cord D1 cGy ‐33 ‐17 ‐34.8  ‐34.8  ‐10
Normal 
tissueV20  0.5  0.4  0.5  0.5  0.4 
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P4P107  Pin  N1  N2  N3  Dtra  
D98 cGy ‐39.7 ‐52 ‐78.6  ‐76.6  8
D50 cGy ‐19.5 ‐14.5 ‐23.8  ‐24.8  ‐12.5
Lung V20 % ‐0.1 0.04 ‐0.02  ‐0.02  0.03
MLD cGy 3.7 5.7 5.3 5.2  5.3
Esophagus 
V25 %  ‐0.5  ‐0.15  0.09  0.1  ‐0.1 
Heart
V40 %  NA  NA  NA  NA  NA 
Cord D1 cGy ‐3.3 ‐15.89 ‐2.7 ‐2  ‐7
Normal 
tissue 
V20 % 
‐0.16  0.15  0.1  0.1  0.1 
 
 
P4P110  Pin  N1  N2  N3  Dtra  
D98 cGy ‐51 ‐46.5 ‐54 ‐55  0.1
D50 cGy ‐19 ‐13 ‐18 ‐18  ‐12.6
Lung V20 % ‐0.03 0.03 0.03  0.03  0.04
MLD cGy 4.7 4.7 4.7 4.7  5
Esophagus 
V20 %  ‐0.2  ‐0.1  ‐0.1  ‐0.1  ‐0.1 
Heart
V40 % 
 
‐
0.003  ‐0.004  ‐0.006  ‐0.005  ‐0.01 
Cord D1 cGy ‐26 ‐15.6 ‐30. ‐30  ‐16.4
Normal 
tissueV20 %  0.12  0.2  0.2  0.2  0.12 
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P4P14  Pin  N1  N2  N3  Dtra  
D98 cGy ‐88 ‐68 ‐81 ‐84  ‐48
D50 cGy ‐8.8 ‐8.6 ‐9.6 ‐9.7  ‐8
Lung V20 % 0.2 0.2 0.2 0.2  0.2
MLD cGy ‐0.8 ‐0.3 ‐0.5 ‐0.5  ‐0.4
Esophagus 
V55 %  0.1  ‐0.2  ‐0.2  ‐0.2  ‐0.2 
Heart
V40 %  ‐0.14  ‐0.1  ‐0.1  ‐0.1  ‐0.1 
Cord D10 
cGy  7.6  ‐1.3  0.6  ‐0.1  1.7 
Normal 
tissueV20 %  0.5  0.6  0.6  0.6  0.6 
 
MD‐
Anderson  Pin  N1  N2  N3 
Dtra 
 
D98 cGy 92 84 82 82  136
D50 cGy 567 48 59 61  23
Lung V20 % ‐0.08 ‐0.05 ‐0.06  ‐0.06  ‐0.07
MLD cGy 2.5 2.4 2.2 2.2  1.4
Esophagus 
V10 %  ‐1  ‐1.2  ‐1.7  ‐1.7  ‐1.4 
Heart
V10 %  ‐0.4  ‐0.4  ‐0.5  ‐0.5  ‐0.5 
Cord D10 
cGy  N/A  N/A  N/A  N/A  N/A 
Normal 
tissueV20 %  ‐0.1  ‐0.4  ‐0.5  ‐0.5  ‐0.5 
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Table 17: 4 mm dose grid DME statistics. 
 
Patient #  Pinn‐EMCM  Dtrans‐EMCM  Nsub1‐EMCM  Nsub2‐EMCM  Nsub3‐EMCM 
  max  avg  SD  max  avg  SD  max  avg  SD  max  avg  SD  max  avg  SD 
100  13.7  ‐0.01  0.68  11.6  0  0.5  12  ‐0.01  0.65  11.3  ‐0.01  0.6  11  ‐0.01  ‐0.6 
101  23.9  0.06  0.76  22  0.06  0.73  22.33  0.06  0.75  22  0.06  0.75  22  0.06  0.75 
102  19.5  0.1  0.97  20  0.1  0.9  22  0.1  0.96  21  0.1  0.9  21  0.1  0.9 
103  11   0.02  0.6  10.33  ‐0.04  0.5  11.4  0.02  0.54  11  0.02  0.54  11  0.02  0.54 
104  17.4   0.01  0.97  17.2  ‐0.004  0.8  17  ‐0.1  0.8  17  ‐0.01  0.8  17  ‐0.01  0.8 
105   9.68  ‐0.02  0.48  6.5  ‐0.01  0.34  7.9  ‐0.03  0.51  7.65  ‐0.02  0.41  7.6  ‐0.02  0.44 
106  12.4  ‐0.03  0.52  8.94  ‐0.02  0.38  6.77  ‐0.03  0.4  6.4  ‐0.03  0.43  6.32  ‐0.03  0.43 
107  10.7  ‐0.003  0.38  6.3  ‐0.001  0.2  7.44  ‐0.0007  0.25  6.3 
‐
0.003  0.31  6.4 
‐
0.002  0.3 
110  9.53  ‐0.01  0.45  4.4  0.02  0.26  5.43  ‐0.008  0.3  4.87  ‐0.006  0.32  4.86 
‐
0.007  0.32 
114  8.7  ‐0.07  0.6  5.7  ‐0.07  0.5  7  ‐0.1  0.76  6.3  ‐0.08  0.58  6.3  ‐0.09  0.6 
MD‐
Anderson  18.7  0  0.5  9.8  0.005  0.2  6.16  0  0.2  4.7  0  0.2  4.8  0  0.2 
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16 Appendix VII 
 
 
Figure 95: scatter plot of discrete versus continuous DTD in mm for patient P4P101.  The two red lines represent 
the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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Figure 96: scatter plot of discrete versus continuous DTD in mm for patient P4P102.  The two red lines represent 
the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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Figure 97: scatter plot of discrete versus continuous DTD in mm for patient P4P103.  The two red lines represent 
the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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Figure 98: scatter plot of discrete versus continuous DTD in mm for patient P4P104.  The two red lines represent 
the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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Figure 99: scatter plot of discrete versus continuous DTD in mm for patient P4P105.  The two red lines represent 
the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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Figure 100: scatter plot of discrete versus continuous DTD in mm for patient P4P106. The two red lines 
represent the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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Figure 101: scatter plot of discrete versus continuous DTD in mm for patient P4P107.  The two red lines 
represent the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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Figure 102: scatter plot of discrete versus continuous DTD in mm for patient P4P110. The two red lines 
represent the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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Figure 103: scatter plot of discrete versus continuous DTD in mm for patient P4P114.  The two red lines 
represent the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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Figure 104: scatter plot of discrete versus continuous DTD in mm for patient MD-Anderson.  The two red lines 
represent the maximum and minimum interpolation error which is equal to √૛*voxel size. 
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17 Appendix VIII 
    
 
(a) 
                                                                  (b) 
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(c) 
Figure 105 : (a) Isodose lines on a single transverse slice of the computed dose for P4P101.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values. (c) Color 
wash of the difference between discrete and continuous DTDs.   Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
 
(a) 
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                                                                      (b) 
 
Figure 106: (a) Isodose lines on a single transverse slice of the computed dose for P4P102.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values.  (c) Color 
wash of the difference between discrete and continuous DTDs.  Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
 
(a) 
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                                                                      (b) 
 
(c) 
Figure 107: (a) Isodose lines on a single transverse slice of the computed dose for P4P103.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values.  (c) Color 
wash of the difference between discrete and continuous DTDs.  Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
 
 
(a) 
 201 
(b) 
 
(c) 
Figure 108: (a) Isodose lines on a single transverse slice of the computed dose for P4P104.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values.  (c)  Color 
wash of the difference between discrete and continuous DTDs.  Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
 
(a) 
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(b) 
 
(c) 
Figure 109: (a) Isodose lines on a single transverse slice of the computed dose for P4P105.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values.  (c) Color 
wash of the difference between discrete and continuous DTDs.  Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
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(a) 
(b) 
 
(c) 
Figure 110: (a) Isodose lines on a single transverse slice of the computed dose for P4P106.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values. (c) Color 
wash of the difference between discrete and continuous DTDs.  Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
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(a) 
(b) 
 
(c) 
Figure 111: (a) Isodose lines on a single transverse slice of the computed dose for P4P107.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values. (c) Color 
wash of the difference between discrete and continuous DTDs.  Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
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(a) 
 
(b) 
 
(c) 
Figure 112: (a) Isodose lines on a single transverse slice of the computed dose for P4P110.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values. (c) Color 
wash of the difference between discrete and continuous DTDs.  Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
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(a) 
(b) 
 
(c) 
Figure 113: (a) Isodose lines on a single transverse slice of the computed dose for P4P114.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values.  (c) Color 
wash of the difference between discrete and continuous DTDs.  Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
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(a) 
 
(b) 
 
(c) 
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Figure 114: (a) Isodose lines on a single transverse slice of the computed dose for MD-Anderson.  The minimum 
prescribed dose (66 Gy) is indicated in blue.  Structures in color wash are CTV (purple), esophagus PRV (blue) and cord 
PRV (orange). (b) Color wash of the discrete (on the left) and 3D continuous (on the right) DTD3.30Gy values.  (c) Color 
wash of the difference between discrete and continuous DTDs.  Each color wash values represent the lower bound of the 
value, e.g. 1 mm corresponds to DTDs ranging from 1.0 to 2.0 mm. 
 
 
 
